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ABSTRACT OF DISSERTATION 
 
 
THE OFF-LABEL USE OF ATYPICAL ANTIPSYCHOTICS AND 
ITS IMPACT ON ATTENTION DEFICIT/HYPERACTIVITY DISORDER (ADHD) 
 
Atypical antipsychotics (AAPs) (also known as second-generation antipsychotics) 
are the US Food and Drug Administration (FDA) approved medications for 
schizophrenia, bipolar I disorder, depression and autism. Compared to the typical 
antipsychotics, AAPs were marketed as reducing adverse side effects such as 
extrapyramidal symptoms. This resulted in extensive use of AAPs for not only the FDA 
approved indications but also other conditions that are not approved. However, several 
post-marketing clinical trials evaluated the use of AAPs and reported serious adverse 
side effects, including metabolic syndrome, cardiovascular events, or death. 
The extensive use of AAPs by pediatrics is an important policy problem that 
imposes serious concerns on public health and economy in the US. A large proportion of 
total pediatric AAP use is off-label in which the safety and effectiveness are not yet 
established. Moreover, among the off-label conditions for which AAPs were used, 
ADHD was the most common primary mental diagnosis.  
From public health perspective, the risk of type II diabetes in pediatric AAP 
users was estimated. A retrospective cohort study was conducted and a twice higher 
risk of developing type II diabetes was estimated for AAP users compared to non-users 
in pediatrics.    
From economic efficiency perspective, the cost-effectiveness of AAPs compared 
to other ADHD medications in pediatric ADHD patients was estimated. Among non-
stimulant ADHD medication treatment strategies, AAPs resulted in the lower expected 
health outcome than other ADHD medications. Also, AAPs were not a favored choice 
with respect to cost-effectiveness. A comparative effectiveness study that compares 
resource utilization and costs between atypical antipsychotic (AAP) users and non-AAP 
users in ADHD revealed that AAP users were likely to visit a healthcare facility for 
outpatient and inpatient services more frequently than non-AAP users. Total health care 
costs were significantly higher for AAP users with additional costs of $1,393 (2012 
dollars) during six months and $2,784 (2012 dollars) during a year after initiating the 
AAP treatment.  
 
KEYWORDS: Atypical antipsychotics (AAPs), Attention-deficit/hyperactivity disorder 
(ADHD), Type II diabetes (T2DM), Cost-effectiveness, Comparative effectiveness 
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Chapter 1: A review of ADHD and concerns related with atypical antipsychotics 
(AAPs) use 
 
A. Introduction 
During the current transition to national healthcare reform, much more attention 
is being paid to how the health care system is implemented than ever before. While it is 
well known that health care reform will affect the number of individuals covered by 
insurance, less is known about the clinical and economic impacts of the Patient 
Protection and Affordable Care Act (PPACA). The PPACA addresses these with titles of: 
1) “Improving the quality and efficiency of health care,” and 2) “Prevention of chronic 
disease and improving public health. “ As described in the book Tracking Medicine, 
written by John Wennberg, the U.S. health care delivery system shows unwarranted 
variation that cannot be explained based on prevalence of illness, medical evidence, or 
patient preference.1 Wennberg argues that undisciplined growth in health care and 
spending has contributed to the overuse of health care resources. 
Antipsychotic medications have long been used for treatment of mental 
disorders including psychosis, schizophrenia and bipolar disorder. These medications 
can be broadly categorized into two classes: (1) conventional antipsychotics, also known 
as first generation antipsychotics or typical antipsychotics, which were discovered in 
1950s.2 (2) Atypical antipsychotics (AAPs) (also known as second-generation 
antipsychotics) were introduced during 1990s. Compared to the conventional 
antipsychotics, AAPs were marketed as reducing adverse side effects such as 
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extrapyramidal symptoms. This resulted in extensive use of AAPs for not only the U.S. 
Food and Drug Administration (FDA) approved indications but also other conditions 
that are not approved. However, several post-marketing clinical trials evaluated the use 
of AAPs and reported serious adverse side effects, including metabolic syndrome, 
cardiovascular events, or death.3-5 Also, controversy exists over whether the unapproved 
use of AAPs is justified in terms of effectiveness and safety.6-9 Nevertheless, AAPs are 
one of the top-selling classes of pharmaceuticals in the US. In fact, antipsychotic 
medications generated about  $18.2 billion total revenue in 2011, with three individual 
AAP agents accounting for 65% of the total revenue.10 
This chapter is intended to review current issues related with unapproved use of 
AAPs, specifically focusing on thier use in attention-deficit/hyperactivity disorder 
(ADHD) children and adolescents. I start by providing general information about 
ADHD such as symptoms, diagnostic process and prevalence, followed by ADHD 
treatment options and costs of illness. Then, I motivate the study rationale for why AAP 
use in ADHD is important from a public health perspective, as well as a social efficiency 
perspective. Next, we give a systematic review of AAP use in the young population and 
the associated clinical side effects. Lastly, with commentary about the systematic review, 
future areas of research will be suggested.  
   
B.  ADHD symptoms, diagnosis, and prevalence 
Attention-deficit/hyperactivity disorder (ADHD) is the most common 
neurobehavioral disorder of childhood, characterized by having trouble paying 
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attention, not being able to control impulsive behaviors, or being overly active.11 Those 
with ADHD may experience academic underachievement, troublesome interpersonal 
relationship development, and low self-esteem. Core ADHD symptoms can be divided 
by two dimensions based on psychometric properties. One is the inattention dimension 
that includes symptoms such as making careless mistakes, having difficulty sustaining 
attention, or being easily distracted. The other is hyperactivity-impulsivity dimension 
that is characterized by symptoms such as being unable to stay seated, having difficulty 
engaging in leisure activities quietly, or interrupting/intruding on others. ADHD 
diagnosis is made when at least six or more core symptoms are present in either or both 
of dimensions. Core symptoms of ADHD adapted from the DSM-IV-TR are shown in 
Table 1. 1. 
The prevalence of ADHD has been increased from 7.8% to 9.5 % during 2003-
2007, according to the Center for Disease Control (CDC) in 2010.12 The increase in 
prevalence can occur when the incidence increases. Some of the increase is due to the 
way of patients are diagnosed or detected. Also, it is likely that the observed increase in 
prevalence is explained by, in part, by the increased recognition of the condition. In fact, 
the CDC report shows that twelve states had significant increases in the number of 
diagnosed ADHD cases and this suggests that state policy or practice changes, such as 
widespread behavioral health screening, could have resulted in the increased prevalence 
rate. Furthermore, the diagnostic and treatment scope for ADHD has expanded as recent 
clinical practice guidelines for ADHD, published by the American Academy of 
3 
 
Pediatrics, expanded the age range of the recommendations from 6-12 years of age to 4-
18 years of age.11  
 
C. Treatment options for ADHD  
 Treatment options for ADHD include medication therapy and behavior therapy. 
According to the ADHD clinical practice guideline, only behavioral therapy is 
recommended for preschool-aged children (4-5 years of age) as the first line treatment. 
For school-aged children and adolescents (6-18 years of age), the combination of 
medication and behavioral therapies is preferred. Medication therapy usually initiates 
with stimulants such as amphetamine derivatives (e.g., Adderall), which are FDA-
approved medications for ADHD. Selective norepinephrine reuptake inhibitor 
(atomoxetine) and selective α2-adrenergic agonists (clonidine, guanfacine) are also FDA-
approved medications for ADHD management and are often considered as alternatives 
or adjunctive therapy with stimulants. FDA-approved medications including their 
generic and brand names are shown in Table 1. 2.  
Typical behavioral therapy includes parent-training programs in which the 
parents or caregivers of children with ADHD are educated with skills to manage 
behavioral symptoms of their child. As another strategy, changing the physical 
environment, such as the classroom, is also considered and recommended because it 
could reduce stimuli that trigger behavioral symptoms. Although it has been shown 
effective for ADHD management, behavioral therapy requires a high level of family 
involvement and it might not be easily accessible for some patients.   
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D. Cost of illness 
The ADHD patients experience substantial difficulties in many areas of their 
lives, including academic underachievement, and impaired social functioning, which 
may impact them the rest of their lives. For example, poorer social functioning among 
ADHD patients was observed in several studies, which report that those with ADHD 
have fewer close friends and are more frequently rejected by peers, compared to those 
without ADHD.15-17 More importantly, according to the findings of Bagwell et al., these 
problems are persistent from childhood to adolescence.15 They retrospectively followed 
adolescents based on their ADHD history and found that impairments in peer relations 
during adolescence were highly predicted by childhood ADHD.    
ADHD also affects families and caregivers in a form of emotional distress or the 
loss of work productivity, due to excessive care-giving effort required by ADHD 
patients.14,18  Swensen et al., estimated medical care costs and costs associated with work 
loss accrued to the family members of ADHD patients.14 They reported that ADHD 
family members had a higher rate of mental disorders compared to their matched 
controls. The prevalence of depression was more than twofold higher in the ADHD 
family members (9% vs. 4%). They also showed that having an ADHD patient in the 
family was associated with higher medical expenses for other family members, as well 
as higher indirect costs generated from work absenteeism.  
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E.  Atypical antipsychotics and ADHD 
Economic burden of ADHD could vary significantly depending on the choice of 
treatment regimen and how well the patient responds to the therapy. For example, 
although the symptoms are successfully managed with stimulants in most ADHD 
patients for the short term (6-10 weeks),19-21 an alternative medication regimen is often 
considered due to the adverse side effects, tolerance development or lack of symptom 
improvement. While atomoxetine, clonidine or guanfacine are recommended as the 
alternative to stimulants, a growing number of ADHD children are prescribed with 
AAPs.8,22,23 The AAP use is concerning because they are not approved for ADHD 
management by FDA nor recommended by ADHD practice guidelines. 
Atypical antipsychotics (AAPs, or second-generation antipsychotics) are a 
relatively new class of antipsychotic medications. Frequently used AAPs are: olanzapine, 
risperidone, quetiapine, ziprasidone, paliperidone, and aripiprazole. Atypical 
antipsychotics are thought to block dopamine receptors as their mechanism of action, 
except aripiprazole. Aripiprazole does not block the dopamine receptor but acts as a 
partial agonist and reduces the receptor activation by competing with dopamine or 
other full agonists. Atypical antipsychotics are FDA-approved for the treatment of 
schizophrenia and bipolar mania, and a few have also been approved for autism 
spectrum disorders and major depression. FDA-approved indications for AAPs and 
their generic/brand names are shown in Table 1. 3. 
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The use of AAPs in children and adolescents with ADHD in practice is 
potentially important from the public health standpoint, as well as economic efficiency 
standpoint.  
 
Public Health Perspectives 
From the public health standpoint, AAP associated adverse side effects could 
impose a considerable health care burden on a number of children and adolescents. 
There are serious adverse side effects reported in AAP users, including obesity, 
metabolic syndrome, cardiovascular events, Type II diabetes, and increased mortality. In 
spite of the severe health risks, ADHD has been reported as one of the most frequent 
conditions for which children and adolescents were prescribed AAPs.8,22,23 Pathak et al. 
examined the dispensing pattern of AAPs using a state Medicaid claims data and 
reported that ADHD was the most common condition for children and adolescents to be 
prescribed with AAPs from 2001 to 2005.8 Also, Cooper et al. reported the same finding 
from the National Ambulatory Medical Care Survey and National Hospital Ambulatory 
Medical Care Survey.22  
In addition to the clinical impact associated with adverse side effects of AAPs, 
ADHD patients taking AAPs are at risk of experiencing drug-drug interactions. More 
specifically, medication therapy in ADHD usually initiates with stimulants and the 
initial stimulant therapy is later augmented with AAPs, or switched to AAPs.24 
Therefore, the drug-drug interaction could occur between stimulants and AAPs as they 
have opposing mechanisms of action, such that stimulants increase dopamine level and 
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AAPs blocks dopamine receptor activation. For this reason, the concurrent use of the 
two medications could potentially mask the underlying chemical imbalance. Moreover, 
several studies have reported that not only concurrent use, but switching from one 
medication to the other also caused movement disorders such as dyskinesia or extra-
pyramidal symptoms.25,26   
 
Economic Efficiency Perspective 
From the economic efficiency standpoint, AAP use in ADHD is concerning 
because a large number of AAPs are possibly misused in the ADHD population. Unlike 
most other mental disorders for which medication therapy is the only treatment option, 
the ADHD clinical practice guideline recommends behavioral therapy accompanied by 
FDA-approved medications.11 Also, it is recommended that prescribers carefully 
consider benefit and harm and make sure the use of medication is beneficial. However, 
it is not clear whether the use of AAPs in ADHD for symptom control outweighs the 
potential harm, because the evidence is limited. Nevertheless, a recent study conducted 
by Sikirica et al., shows that approximately one in eight ADHD patients who initiated 
medication therapy with a stimulant were prescribed AAPs before trying other FDA-
approved medications.24 Sikirica et al., also estimated resource utilization and costs of 
stimulant-treated ADHD children who switched to or augmented their stimulant 
treatment with atypical antipsychotics compared with non-antipsychotic medications. 
Using samples matched based on propensity to receive an AAP, they found that the 
AAP cohort had higher mean all-cause and mental health-related costs compared to the 
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non-AAP cohort ($7,407 vs. $5,072; $5,402 vs. $3,054, respectively in 2012 US $; all 
P<0.001). Therefore, if AAPs are misused for ADHD, the economic impact for society 
will be substantial considering the high costs involved in AAP use and the number of 
individuals affected. 8,22,23  
 
F. Systematic review of adverse side effects associated with AAP use in children and 
adolescents. 
The effectiveness and safety of AAPs are not yet established in children and 
adolescents. Prior studies about AAP-related adverse side effects in children and 
adolescents are not ADHD-specific. Also, the study design, patient inclusion criteria, 
and methodological approaches to control for confounding vary among studies. 
Although there are more studies about increased mortality in the elderly population27 or 
the increased risk of diabetes/cardiovascular disease in adults,28-30 fewer studies exist in 
children and adolescents to evaluate those risks. A majority of studies that are focused 
on AAP adverse effects in children and adolescents examined weight gain. Key findings 
of selected studies about three major AAP- related side effects, namely weight gain, 
Type II diabetes, and cardiovascular event, are summarized in this section.   
This literature review is based on the literature from Medline search, with the 
Mesh terms of:  “child”, “adolescent”, “metabolic syndrome X”, “diabetes mellitus”, 
“dyslipidemia”, “cardiovascular disease”, “hypertension”, “hyperglycemia”, 
“overweight”, “obesity”, and “weight gain”. Also, the search was restricted to the Mesh 
major topic of “antipsychotic agents/adverse effects”, in order to retrieve articles where 
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the adverse effects are the major focus of the article. All retrieved articles were further 
culled by excluding non-English written articles, letters, news and adult population 
based studies.i (Figure 1.1) The search was conducted on April 25, 2013. 
It should be noted that the search terms that were used in this study may not 
capture articles that reported adverse side effects as a secondary outcome. We sought to 
search the studies that focused mainly on adverse side effects of AAPs. However, our 
search terms potentially miss some of the randomized controlled trials in which drug 
effectiveness is the primary outcome, while side effects are reported as well.    
   
Weight Gain 
Findings from prior studies are consistent in indicating that children and 
adolescents who used AAPs are likely to gain weight. From the Medline search, two 
review articles and nine primary studies that specifically focused on AAP-induced 
weight gain in children and adolescents were identified. Both review articles observed 
significant weight gain related with the AAP use in younger population. 31,32 Original 
articles about weight gain associated with AAPs are summarized in Table 1. 4. The 
average weight gain among AAP users was 7.45 kg (± 2.33) in 6 months if it is assumed 
that the rate of weight gain is consistent over time.33-40 Interestingly, the rate of weight 
gain differs by agent according to studies conducted by Fleischhaker et al., which 
compared clozapine, olanzapine and risperidone in the follow-ups of 6 weeks and 45 
i In the Mesh database, “adolescent” refers to a person 13 to 18 years of age. Some papers target 
adult population and include study subjects who are age 18 or greater. However, since they 
include those with age 18, the paper will include the Mesh term of “adolescent” in addition to 
“adult”. Such papers were excluded because those are mainly adult population based. 
10 
 
                                                     
weeks.36,37. The average weight gain at the 6 week follow up was the highest in 
olanzapine (4.6kg) followed by risperidone (2.8kg) and clozapine (2.5kg). At the 45-week 
follow up, olanzapine still showed the highest weight gain (16.2kg) but followed by 
clozapine (9.5kg) and risperidone (7.2kg). That is, having olanzapine is associated with 
the fastest weight gain throughout the study period (45 weeks), risperidone showed 
faster weight gain than clozapine in the short term (6 weeks), but clozapine became 
faster in the longer term (45 weeks). Correll et al., also examined agent-specific weight 
gains using olanzapine, quetiapine, risperidone, and aripiprazole, compared with a non-
user group.40 In their study, olanzapine was associated with the highest weight gain, 
which is consistent with the finding of Fleischhaker et al. In addition to the studies 
focusing on children and adolescents, there were three articles that studied age-
dependent effects.41-43 All three articles concluded that the change in weight was 
significantly larger in children and adolescents, compared to adult patients.   
 
Type II Diabetes 
 There were few clinical studies that examined the association between AAP use 
and type II diabetes in children and adolescents. (Table 1. 5.)ii Panagiotopoulos et al., 
conducted a cross-sectional study using laboratory test results to identify type II 
diabetes patients and found a significantly higher rate of type II diabetes among the 
ii Because the systematic review search was conducted in April 2013, a retrospective cohort study 
published by Bobo et al. in October 2013 was not included in this report. Bobo et al. reported the 
three times higher risk of type II diabetes among antipsychotic users compared to other 
psychotropic medication users in children and youth 6 to 24 years of age.    
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AAP user group, compared to the non-user group.44 However, they did not account for 
any confounders in the analysis and it is possible that the higher prevalence of type II 
diabetes among the AAP user group is not necessarily associated with AAP use. 
McIntyre et al. used a state Medicaid database and adjusted for age, sex and ethnicity in 
their retrospective cohort study.45 They reported a statistically significant impact of 
multiple AAP use on type II diabetes that was identified using ICD-9-CM (OR: 2.36; 95% 
CI: 1.13-4.92). However, their current user design could have overestimated the impact 
of AAP on the probability of Type II diabetes development. Current user design is a 
study design where the subjects are identified on the basis of current exposure, without 
tracking the past exposure. The current user design could introduce bias since the 
disease risk factors that may be altered by the study drug cannot be controlled. Andrade 
et al., on the other hand, used a new user design and matched samples using propensity 
scores in order to adjust for possible selection bias on AAP use.46 They conducted a 
retrospective cohort study and compared the AAP new users to non-users, as well as to 
antidepressant users (active comparator). While AAP users were more likely to develop 
Type II diabetes compared to non-users in unadjusted analysis (IRR: 4.24; 95% CI: 1.95-
8.72), when the two groups were matched using propensity scores, the impact of AAP 
became not significant (IRR: 4.47; 95% CI: 0.23-263.82). Also, when they compared AAP 
users to antidepressant users, the likelihood of Type II diabetes development was not 
significantly different either in unadjusted analysis or propensity score matching 
analysis.  
12 
 
 There were two studies that did not specifically focus on children/adolescents 
but looked at the age-stratified relationship.32,47 One of the studies analyzed the US Food 
and Drug Administration (FDA) Adverse Event Reporting System (AERS) and they 
reported that in the 0-17 years of age group, a 95% likelihood of diabetes-related adverse 
events (DRAEs) occurred at least two times more frequently than expected.47 The other 
study that examined the age-dependent relationship used the current user study design 
and found that the association between diabetes and AAPs use was stronger in younger 
patients.32 For patients aged 0-24 years, the impact of clozapine, olanzapine and 
risperidone was strongest among all of the age groups (clozapine OR 20.4; 95% CI: 7.5-
54.9, olanzapine OR 8.2; 95% CI:4.4-15.4, risperidone OR 6.1; 95% CI: 3.8-9.7).    
 
Cardiovascular Events 
From the Medline search, one article was identified for cardiovascular events 
associated with AAP use in children and adolescents. McIntyre et al. conducted a 
retrospective cohort study and examined AAP-related cardiovascular events in children 
and adolescents at two levels of comparison in a Medicaid population: the primary 
comparison was performed between AAP users and non-users and secondary 
comparison was performed between single AAP users and multiple AAP users. 
Cardiovascular events included ischemic/pulmonary heart disease, arrhythmias and 
cardiomegaly.45 The paper reported that the odds of having a cardiovascular event was 
significantly higher for multiple AAPs users than single AAP users.  
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G.  Need for evidences from well-designed research 
 Observational studies are useful in examining drug associated side-effects that 
require a long-term follow-up. Although there are prior studies providing the evidence 
of risks associated with AAPs, the number of studies that attempt to control for 
confounding is still limited.  
 The observed variation in findings in the literature is likely due to different 
methods used to avoid confounding and bias. In other words, each study included 
different confounders in their analyses and therefore, the impact of AAP use would have 
been adjusted differently depending on the strength of correlation between the AAP use 
and other confounders. Also, different study designs and methodological approaches 
can result in different conclusions. Andrade et al. conducted both adjusting and 
matching analysis. In result, the AAP use was shown to have a significant impact on 
diabetes development when using the adjusting method, but the association was not 
significant in the propensity score matching analysis. The estimates from the two 
methods could be different if a selection bias is present in the study design. More 
specifically, adjusting controls for other confounders that are associated with treatment 
and also with the outcome so that the estimate of treatment reflects the independent 
impact of AAP. However, matching attempts to control for potential selection bias in 
which the treatment group has a differential impact on the outcome regardless of the 
treatment, by selecting samples that are only different in treatment, but otherwise 
similar to each other.  
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However, analytical method is not the only explanation for the different 
conclusions. Criteria for identifying AAP users could have impacted the findings as well. 
For example, McIntyre et al. reported a statistically significant impact of AAP on Type II 
diabetes using current user design, but this could make the interpretation of the result 
arguable whether the observation of current users yields the unique impact of AAP on 
the probability of Type II diabetes development. Because non-randomized studies often 
lack detailed historical data on pretreatment information, it is more credible to restrict 
the treatment group to new users so that the estimate is more internally valid.  
 
H. Areas of future research 
Although it is not specific to the ADHD population, prior studies have warned to 
be cautious about using AAPs in children and adolescents due to their adverse effects. 
Due to potentially important implications in public health as well as efficient resource 
allocation, the use of AAPs in the ADHD population needs to be assessed with a 
multidisciplinary approach that examines how the exposure to atypical antipsychotics 
clinically affects the young population, and what the economic consequences of the 
treatment are. Therefore, my dissertation research will address underlying problems 
about AAP utilization, and its implication to ADHD children and adolescents. In chapter 
1, detailed backgrounds about ADHD and issues related with AAPs were provided from 
literature review. Then, in chapter 2, the national utilization trend of AAPs, off-label 
practice, and use in ADHD is examined. The chapter further inspects the trend by payer 
source, and regional variations in the US. In chapter 3, as one of the potential adverse 
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effects, the risk of Type II diabetes in pediatric AAP users is estimated. Combined with 
chapter 2, the findings of this chapter will suggest the magnitude of risk that is imposed 
on the pediatric population in the U.S. While chapters 2 and 3 focus more on AAP 
utilization in general and assess the potential impact on ADHD, following chapters 
restrict the population specifically to ADHD patients and look into the impact of the 
drug on the ADHD specific patient level. Chapter 4 estimates the cost-effectiveness of 
AAPs in ADHD from literature review. Then, chapter 5 presents an original study that 
compares resource utilization and costs between atypical antipsychotic (AAP) users and 
non-AAP users in ADHD. 
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Table 1. 1. Core symptoms of ADHD adapted from DSM-IV-TR 
 
 
Source: Clinical practice guideline for the diagnosis, evaluation, and treatment of 
attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics 
2011;128:1007-22. 
 
 
 
 
 
 
 
 
 
 
Inattention Dimension Hyperactivity-Impulsivity Dimension 
 Hyperactivity Impulsivity 
Careless mistakes Fidgety 
Blurts answers before 
questions 
Difficulty sustaining 
attention Unable to stay seated Difficulty awaiting turn 
Seems not to listen 
Moves excessively 
(restless) 
Interrupts/intrudes on 
others 
Fails to finish tasks 
Difficulty engaging in 
leisure activities quietly  
Difficulty organizing "On the go"  
Avoid tasks that require 
sustained attention Talks excessively  
Loses things   
Easily distracted   
Forgetful   
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Table 1. 2. FDA-approved ADHD medications 
 
Medication Brand name Route 
Generic 
form 
available 
Mixed amphetamine salts Adderall Oral √ 
 Adderall XR Oral √ 
Dextramphetamine Dexedrine/Dextrostat Oral √ 
 Dexedrine Spansule Oral √ 
Lisdexamfetamine Vyvanse Oral  
Methylphenidate Concerta Oral  
 Methy ER Oral  
 Methylin Oral  
 Daytrana Transdermal  
 Ritalin Oral √ 
 Ritalin LA Oral  
 Ritalin SR Oral √ 
 Metadate CD Oral  
Dexmethylphenidate Focalin Oral √ 
 Focalin XR Oral  
Atomoxetine Strattera Oral  
Extended-release guanfacine Intuniv Oral  
Extended-release clinidine Kapvay Oral  
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Table 1. 3. Atypical antipsychotics and FDA-approved indications 
 
Medication FDA indication Brand 
Generic form 
available 
Aripiprazole 
Schizophrenia, bipolar I 
disorder, adjunctive to 
majore depression 
Abilify  
Asenapine 
Maleate 
Schizophrenia, bipolar 
mania 
Saphris  
Clozapine Treatment-resistant 
schizophrenia 
Clozaril √ 
Iloperidone Schizophrenia Fanapt  
Lurasidone Schizophrenia Latuda  
Olanzapine Schizophrenia Zyprexa  
  
Zyprexa 
relprevv  
  Zyprexa zydis  
Olanzapine/Fl
uoxetine 
Depressive episodes 
associated with bipolar I 
disorder, treatment resistant 
depression 
Symbyax  
Paliperidone Schizophrenia Invega  
  
Invega 
sustenna 
 
Quetiapine Schizophrenia, bipolar 
mania, bipolar depression 
Seroquel √ 
 Seroquel XR  
Risperidone 
Schizophrenia, bipolar I 
disorder, autism 
Risperdal √ 
 Risperdal 
consta 
 
Ziprasidone Schizophrenia, bipolar I 
disordermajore depression 
Geodon √ 
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Figure 1. 1. Flowchart of review article selection 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* In the Mesh database, “adolescent” refers to a person 13 to 18 years of age. Some 
papers target adult population and include study subjects who are age 18 or greater. 
However, since they include those with age 18, the paper will include the Mesh term of 
“adolescent” in addition to “adult”. Such papers were excluded because those are 
mainly adult population based. 
** The article about the risk of cardiovascular events also reported about Type II diabetes, 
and it appears twice in the figure. 
 
 
 
 
 
Copyright © Minji Sohn 2014 
200 full text articles about antipsychotic agent adverse effects in children/adolescent 
124 Adult studies*, 3 small number samples (n<10), 3 
news, 24 letters, 7 non-English written articles, 12 side 
effect treatment articles, and 10 side effect mechanism 
articles 
8 Original articles (Table 1. 4),  
2 adult-children/adolescent comparison studies, 
2 literature reviews 
3 Original articles (Table 1. 5) 
2 adult-children/adolescent comparison studies 
1 Original article** 
Excluded articles 
Weight gain 
Type II diabetes 
Cardiovascular events 
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Chapter 2: National trends in atypical antipsychotics in children and adolescents 
 
A. Background 
As a result of the intense marketing campaigns promoting atypical 
antipsychotics (AAPs) as a safer alternative  (i.e., reducing the risk of side effects like 
extrapyramidal symptoms) to conventional antipsychotics, and despite the safety 
concerns (i.e., metabolic syndrome, cardiovascular events, or death)3-5 raised by post-
marketing studies in adults, AAP use has increased not only for indications approved by 
the US Food and Drug Administration (FDA) but also for other conditions.48 In children 
and adolescents in the US, AAPs are probably among the most increasingly used classes 
of prescription drugs.49,50 In a study using data from three Medicaid programs and one 
private managed care organization in the U.S., the total AAPs use for children and 
adolescents increased 1.5- to 3-fold between 1996 and 2001.50 Also, medical office visits 
including antipsychotic medications for youth patients increased 5-fold between 1993 
and 2002.51 However, to the best of our knowledge, previous trend analyses for the 
pediatric AAP use have not been updated for more recent years. Also, it would be 
essential to understand the current trend of pediatric AAP use and characteristics before 
discussing the clinical/economic benefits and costs. Therefore, the purpose of this 
chapter is to (1) examine the historic trend of AAP use in the US among 4- to 18- year-
old patients, (2) assess the characteristics of AAP use by identifying primary mental 
disorders and frequently used AAP agents, and (3) estimate the strength of independent 
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association of patient/provider characteristics with AAP prescription among pediatric 
(4- to 18- year-old patients) ADHD visits.  
 
B. Materials and methods 
Data source 
Data sources for this study were the National Ambulatory Medical Care Survey 
(NAMCS) and the National Hospital Ambulatory Medical Care Survey (NHAMCS). The 
NAMCS and NHAMCS are national surveys that collect data on outpatient visits to non-
federal employed, office-based physicians who are primarily engaged in direct patient 
care and outpatient departments of non-institutional general and short-stay hospitals. 
We intended to estimate the national trend of non-emergent visits that are relevant to an 
AAP prescription. For this reason, we did not analyze data collected from hospital 
emergency departments and ambulatory surgery centers.  
 In the NAMCS/NHAMCS data, each visit has information about patient socio-
demographics, physician characteristics, diagnoses, and prescription drugs. Up to three 
diagnoses were recorded per visit using the International Classification of Diseases, Ninth 
Revision, Clinical Modification (ICD-9-CM). The maximum number of drugs that could be 
recorded per visit was six during 1995-2002, and it increased to eight in 2003. Following 
the National Center for Health Statistics recommendation,52 we included only six first-
listed drugs in most of years (between 1995 and 2010) to avoid overestimating the 
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prescribing rate that may be affected by the change in the number of drugs was recorded. 
However, five drugs were included in the analysis for the years of 1993 and 1994.iii  
The data from 1993 to 2010 were used to compute the annual average rate of 
pediatric AAP visits. The data from 2007 to 2010 were combined and analyzed to assess 
the characteristics of pediatric AAP visits (i.e., primary mental disorders and frequently 
used AAP agents) and to identify predictors of AAP use in pediatric ADHD visits. 
Sample weights were applied in all analyses using Stata statistical software, version 12.  
 
Definition of an AAP visit 
 An outpatient visit was regarded as an AAP visit if one or more following 
medications are present: risperidone, olanzapine, quetiapine, ziprasidone, aripiprazole, 
paliperidone, asenapine, and iloperiodone. For 1993-2005, the National Center for 
Health Statistics (NCHS) provided generic codes were used to identify AAPs. Then, 
beginning in 2006, NAMCS/NHAMCS changed the drug identification method by 
implementing Multum codes. Also, AAP visit rates for FDA approved indications were 
estimated. I defined an AAP visit for FDA approved indication as an AAP visit with a 
record of one or more indications that are approved by FDA for any age group at a 
given study year. Even if a pediatric patient was prescribed an AAP with an indication 
that is only approved for adults, I still considered that as the AAP use for a FDA 
iii The years of 1993 and 1994 had up to five drugs that could be entered. Although the National 
Center for Health Statistics recommends using the consistent number of drugs throughout the 
study period when performing trend analyses, we considered that the contribution of these two 
years to the overall trend analysis was minimal and that including five drugs in 1993-1994 and six 
drugs in 1995-2010 in the analyses would not result in overestimation of an actual increase in 
prescribing an AAP during 1995-2010.  
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approved indication. During 1993-2010, AAPs were approved by FDA for four 
conditionsiv; (1) schizophrenia (ICD-9-CM, 295), (2) bipolar disorder (ICD-9-CM, 296.0; 
296.1; 296.4-296.8), (3) depression (ICD-9-CM, 296.2; 296.3; 300.4; 311.X), and (4) autism 
(ICD-9-CM; 299.0).  Figure 2. 1 depicts FDA approved indications for each AAP agent 
throughout the study period. 
 
National trend of AAP visit (1993-2010) 
As the first objective of the study, we examined the national trend of AAP visits 
by calculating average AAP visit rates among 4- to 18- year-old patients for each survey 
year between 1993 and 2010.  
Based on the major events occurred related to AAP use during the period, I 
combined survey years and formed three phases in a way that a new phase began when 
additional indication was approved by FDA for AAP use. For each phase, the average 
visit rate with 95% confidence interval (CI) was calculated. Then, we explored whether 
there were newly available AAP agents or additional FDA warnings during each phase.  
 
Mental diagnoses related with AAP visit (2007-2010 combined) 
 We used three recorded diagnoses of AAP visits to examine (1) whether there 
was any mental diagnosis (ICD-9-CM, 290.XX-310.XX) in the visit, (2) if one or more 
mental diagnoses were present, whether there was any diagnosis for the FDA approved 
iv Olanzapine was approved for the manifestations of psychoses (ICD-9-CM; 290.XX-299.XX) 
between 1996 and 2000. In 2000, the FDA changed the approval for olanzapine to schizophrenia 
and bipolar disorder.   
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indication (as defined above), and (3) if there were one or more mental diagnoses but 
none of FDA approved indications, what was the first-listed mental diagnosis in the visit.  
For the mental health visits without an FDA approved indication, the first-listed mental 
diagnosis was classified into following categories: (1) psychoses with origin specific to 
childhood (“psychoses” hereafter, ICD-9CM, 299.X), (2) disturbances (ICD-9CM, 312.XX; 
313), (3) neurotic disorders (ICD-9CM, 300.0X; 300.1X, 300.2X, 300.3; 300.5; 300.8X; 300.9) 
and (4) other mental disorders (ICD-9-CM, other codes between 290.XX-310.XX). 
 
Factors associated with an AAP prescription in pediatric ADHD visits (2007-2010 combined) 
The data from 2007 to 2010 were combined and analyzed to estimate 
independent associations of patient demographic/socioeconomic characteristics (age, sex, 
race, region of residence, household income/education level based on ZIP code, and 
payer source), physician characteristics (provider type, metropolitan statistical area 
located), and patients’ health information (presence of hyperactivityv, number of non-
AAP drugs, other comorbidities) with an AAP prescription among pediatric ADHD 
visits.  A logistic regression model was developed including these covariatesvi and odds 
ratios with associated 95% confidence intervals were estimated.  
Among 4- to- 18-year-old ADHD patient visits during 2007-2010, 4 percent had 
missing observations for variables that were based on patient ZIP code, such as median 
v There are two ICD-9-CM codes for ADHD: attention deficit disorder without hyperactivity 
(314.00) and attention deficit disorder with hyperactivity (314.01) 
vi Covariates were included in the logistic regression model regardless of its statistical 
significance. That is, even if a covariate was not significant at 5% significance level, it was still 
controlled in the model. 
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household income and percent of Bachelor’s degree or higher. These missing 
observations were not included in the analysis.  However, I used imputed data for 
observations missing a race variable. There were 29 percent missing observations for the 
race variable during 2007-2010 and I used NAMCS/NHAMCS provided imputation 
values for those missing observations. The method used by NAMCS/NHAMCS for 2007 
and 2008 data to impute the race value was based on the patient’s locality (ZIP code or 
state/county of residence), physician locality, specialty, or 3-digit ICD-9-CM code for 
primary diagnosis. If all failed to assign the race value, the imputation was done based 
on a randomly selected record. For 2009 and 2010 data, race was imputed using a model-
based, single, sequential regression imputation method. The model for imputing race is 
described in more detail in the 2009-2010 NAMCS/NHAMCS Public Use Data File 
Documentation.53  
   
C. Results 
National trend of AAP use  
From 1993 to 2010, the overall AAP use showed an increasing pattern. (Figure 2. 
2) When risperidone became first available in 1993, NAMCS/NHAMCS did not have a 
sample visit indicating a pediatric AAP use, as well as in 1994. Starting from 1995, the 
rate of AAP prescription increased gradually until 1999. Between 1999 and 2000, the 
average AAP visit rate increased more than twice from 0.4 per 100 visits to 0.9 per 100 
visits. Then, the increased rate maintained at a stable level until 2002. Then, the average 
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rate increased twice again from 2002 to 2003 (from 0.8 per 100 visits to 1.6 per 100 visits), 
after which average visit rates showed a more fluctuating pattern.  
Based on FDA approvals for additional AAP indication, I combined survey years 
and formed three phases: (1) phase I for the 1993-1999 period, (2) phase II for the 2000-
2002 period, and (3) phase III for the 2003-2010 period. More specifically, each phase 
begins with a newly approved indication for AAP use. It was observed that the average 
visit rates between these phases were statistically different at 5% significance level. 
During phase I, the average AAP visit rate was 0.15 per 100 visits (95% CI, 0.1-0.21 per 
100 visits). Three AAP agents were available in the market with two FDA approved 
indications during the period. Then, the average AAP visit rate increased significantly to 
0.81 per 1000 visits (95% CI, 0.54-1.21 per 100 visits) in phase II. During the period, two 
additional AAP agents became available (total five agents available in the market). Also, 
olanzapine was first approved for bipolar disorder in 2000 and it remained as the only 
AAP agent approved for the indication until 2002. In phase III, the average AAP visit 
rate was 1.59 per 100 visits (95% CI 1.37-1.83). During phase III, three new AAP agents 
became available (total eight agents available in the market) and the FDA approved 
AAPs for more indications including depression and autism. Moreover, the pediatric 
AAP use was first approved during this period.vii  
vii Readers should be reminded that I did not restrict the definition of FDA approved AAP 
indication into specific age group (i.e., even if a pediatric patient was prescribed an AAP with an 
indication that is only approved for adults, I still considered that as the AAP use for FDA 
approved indication). I identified additionally approved indications age-specifically (adult and 
pediatric) only for the purpose of exploring events occurred during each phase.   
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Throughout the study period, a majority of AAP visits did not include a 
diagnosis for FDA approved indications (referred to as “off-indication” in the Figure 2. 
2). The off-indication visits accounted for approximately 86 percent of pediatric AAP 
visits during 1995-2003 and 71 percent during 2004-2010. A statistically significant 
increase for FDA approved AAP use was observed between 2003 and 2004, when three 
AAP agents including aripiprazole, quetiapine, and ziprasidone were approved for 
bipolar disorder in addition to their previously approved indication, schizophrenia.   
 
Mental diagnoses related with AAP visit  
 The estimated number of total outpatient AAP visits among 4- to 18- year-old 
patients during 2007-2010 was 8,380,436 (weighted count) which accounted for 
approximately 2 percent of total pediatric outpatient visits in the U.S.. Of those, 34% 
visits included one or more diagnoses of FDA approved indications. (Figure 2. 3) Within 
this group, a majority of visits had diagnoses of bipolar disorder or depression (16% or 
14% of total pediatric AAP visits, respectively), followed by autism and schizophrenia (5% 
or 1% of total pediatric AAP visits, respectively). Approximately 2% of total pediatric 
AAP visits had two of more diagnoses of FDA approved indications.  
 Among the pediatric AAP visits without any FDA approved indications, ADHD 
was the most common primary mental diagnosis (24% of total pediatric AAP visits), 
followed by psychoses (14% of total pediatric AAP visits). Disturbances and neurotic 
disorders took up about 5% of total pediatric AAP visits respectively. Approximately 15% 
of total pediatric AAP visits did not include any mental disorder diagnosis.  
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Frequently prescribed atypical antipsychotics 
 Of the 8,380,436 total pediatric AAP visits, a majority of visits prescribed 
risperidone, aripiprazole or quetiapine (35%, 32%, or 18% of total pediatric AAP visits) 
(Figure 2. 4). A smaller proportion of visits prescribed ziprasidone, olanzapine, or 
paliperidone (6%, 5%, or 1% of total pediatric AAP visits). Approximately 3% of total 
pediatric AAP visits prescribed two or more AAPs.  
 
Factors associated with an AAP prescription in pediatric ADHD visits 
 During 2007-2010, the total number of pediatric ADHD visits was estimated to be 
31,501,209. Of those, 12% included one or more AAP prescriptions (weighted count: 
3,763,296). Baseline characteristics of pediatric ADHD visits are summarized in Table 2. 
1. Between AAP visits and non-AAP visits, patient demographics and health care 
provider characteristics were not statistically significantly different. However, 
significantly larger proportion of AAP visits had Medicaid as the primary source of 
payment. In terms of ADHD characteristics, AAP visits were more likely to have 
attention deficit disorder with hyperactivity compared to those without hyperactivity. 
Also, AAP visits had more drugs (other than AAPs) prescribed compared to non-AAP 
visits. Baseline comorbidity profile was also different in a way that AAP visits had more 
comorbid conditions including FDA approved AAP indications, psychoses, neurotic 
disorder, disturbance and diabetes.  
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 In the logistic regression analysis, having Medicaid as the primary payment 
source, more prescription medications, and comorbid mental disorders including FDA 
approved AAP indications, psychoses, neurotic disorder, disturbance or diabetes 
significantly increased the likelihood of having an AAP prescription in a pediatric 
ADHD visit. (Table 2. 2) However, having comorbid obesity decreased the likelihood of 
having an AAP prescription.   
 
D. Discussion 
 The purpose of this study was to examine the national trend of pediatric AAP 
use in an outpatient health care setting in the US. The average AAP visit rates were 
estimated each year between 1993 and 2010, and events related with AAP use were 
explored during the period. Then, mental diagnoses related to AAP prescription and 
frequently used AAP agents were assessed for the period of 2007-2010. Lastly, we 
estimated the strength of independent association of patient/provider characteristics 
with AAP prescription among pediatric ADHD visits.  
 From 1993 and 2010, the overall visit rates of AAP prescription in pediatric 
outpatient visits showed an increasing pattern. There was approximately 5-fold 
significant increase from phase I (1993-1999) to phase II (2000-2002) and two-fold 
significant increase from phase II to phase III (2003-2010). When comparing with AAP 
related events occurred during each phase, as more AAP agents became available and 
more AAP indications were approved by FDA, the AAP visit rates also increased 
(Figure 2. 2). Also, it appeared that sudden increases of AAP visit rates were associated 
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with an FDA approval for an additional AAP indication. More specifically, in all AAP 
drug approval processes during 1993-2010, all AAP agents became initially available for 
schizophrenia. Years later, some AAPs changed labels by including additional 
indications including bipolar disorder, depression, and autism. Interestingly, bipolar 
disorder was first approved to be treated with olanzapine among AAP agents in 2000, 
and in the same year, there was an abrupt increase in AAP visit rates, which eventually 
initiated the next phase. Olanzapine was first approved for treatment of depression in 
2003, and there was another abrupt increase in AAP visit rates leading to the next phase 
in the same year. Although it was less abrupt, when autism was first approved to be 
treated with risperidone in 2006, the AAP visits also showed the highest rate since the 
first depression approval in 2003. However, it is hard to argue that such increased visits 
are mostly to treat the additionally approved indication. For example, from phase I to 
phase II, AAP visits for FDA approved indications increased only 0.09 per 100 pediatric 
outpatient visits, while AAP visits for off-indication uses increased 0.57 per 100 pediatric 
outpatient visits. Similarly, from phase II to phase III, the increase in visits for off-
indication usage was larger than for FDA approved indication. One of the plausible 
explanations for this phenomenon might be that having an approval for additional AAP 
indication impacted the AAP therapy decision-making process in a way that an AAP 
agent was thought to be also effective for conditions other than currently approved 
indications. However, my trend analysis does not control for any covariates and 
therefore, further investigation using carefully designed models is needed to clarify the 
association of a certain event with AAP visit rates.  
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My analysis for identifying mental diagnoses that are seemingly related with 
AAP prescription revealed that approximately 66 percent of total pediatric AAP visits 
did not include a diagnosis for FDA approved indications between 2007 and 2010. Of 
those, ADHD was the most common primary mental diagnosis. This finding is 
consistent with several previous studies that examined pediatric AAP use. Pathak et al. 
examined the dispensing pattern of AAPs using Arkansas Medicaid claims data and 
reported that ADHD was the most common condition for children and adolescents to be 
prescribed with AAPs between 2001 and 2005.8 Cooper et al. reported the same finding 
from the NAMCS/NHAMCS data between 1995 and 2002.22 Also, approximately 15 
percent of total pediatric AAP visits did not include any mental diagnosis. A similar 
problem was previously concerned by Staller et al. who reported that 77 percent of 
outpatient antipsychotic visits by 18 year-old or younger patients did not have a mental 
diagnosis. They collected medical and prescription data from eight outpatient clinics in 
central New York in 2002. The fact that they had a much higher proportion of 
psychiatric visits without a mental diagnosis than my study could be explained a 
number of factors including different sampling method, different number of recorded 
diagnoses, or different inclusion criteria in defining antipsychotic visits. Nonetheless, 
both studies raise an important issue about current antipsychotic prescription pattern 
which suggests that antipsychotic medications could be frequently misused in pediatric 
population.  
From my logistic regression model estimating the association between several 
factors and AAP prescription among pediatric ADHD visits, patient demographics and 
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health care provider characteristics did not show a significant association with AAP 
prescription. Instead, patients’ medical profiles showed much stronger associations with 
AAP prescription. More specifically, having more co-prescribed medications (i.e., other 
than AAPs) and comorbid mental disorders including FDA approved AAP indications, 
psychoses, neurotic disorder and disturbance increased the likelihood of having an AAP 
prescription. This result indicates that an AAP is more likely to be prescribed to ADHD 
patients when multiple health conditions are present, controlling for other patient/health 
care provider characteristics. The result of Medicaid being a significant factor could be 
also explained with this result, since chronic illness and other health risk factors are 
more prevalent among Medicaid enrollees compared to those who are covered by a 
private insurance. 54-56     
 There are some limitations that should be noted. First, the survey may not 
capture sufficient information to estimate the AAP visit rates and characteristics of visits. 
I used six first-listed medications and three diagnosis codes for the study period. 
However, such limited availability of medical/pharmacy records may have 
misrepresented the true estimates in the study. For example, it is possible that some 
AAP treated patients had a severe physical illness in addition to mental disorders, and 
due to the limited space for the number of diagnosis codes on the survey form, their 
health care providers were only able to record diagnoses for physical illness. In this case, 
the visit data would have been categorized as an AAP visit with no mental disorder 
diagnosis code, although the visit actually had a mental disorder diagnosis. Second, 
NAMCS/MHAMCS for 1993-2010 were designed to obtain the national/regional estimate 
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of outpatient health care service measures. However, due to insufficient sample size, 
state-level estimates are usually unreliable. For this reason, we were unable to 
independently assess the association of states with the AAP prescription among 
pediatric ADHD visits. Third, due to the nature of micro visit level data, the temporal 
relationship of explanatory variables and AAP prescription was not identifiable. In other 
words, it is not possible to conclude that having comorbid conditions triggered the AAP 
use. Instead, we only know that comorbidities are associated with AAP use.  Fourth, 
variables of obesity, diabetes and cardiovascular disease in our logistic regression model 
had only few observations, making the estimated values unreliable. Especially, the 
variable of cardiovascular disease was dropped from the estimation, because there was 
no variability between AAP prescription and cardiovascular disease. This is probably 
due to the small number of observations in the variable of cardiovascular disease.  
 In conclusion, I showed that outpatient visits including an AAP among 4- to 18-
year-old patients has significantly increased between 1993 and 2010 in the US, and over 
65 percent of those visits did not have diagnoses for FDA approved AAP indications. 
During 2007-2010, the most common mental disorder was ADHD, accounting for 24 
percent of total pediatric AAP visits. Among visits with ADHD diagnosis, those with 
comorbid mental disorders such as psychoses, neurotic disorder and disturbance were 
more likely to have an AAP prescription. 
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Figure 2. 2. Atypical antipsychotic use for children and adolescents (ages 4-18) 
 
 Phase I Phase II Phase III 
Newly available 
AAP agent 
risperidone, 
olanzapine, 
quetiapine 
 
ziprasidone, 
aripiprozole 
 
paliperidone, asenapine, 
iloperidone 
Newly approved 
indication (adult) 
schizophrenia, 
manifestations of 
psychoses* 
 
bipolar I 
disorder 
depression 
Newly approved 
indication 
(pediatric) 
  schizophrenia, bipolar I 
disorder, depression, 
autism 
 
FDA warning   metabolic syndrome, 
increased death in 
elderly dementia patients 
 
*Olanzapine was approved for the manifestations of psychoses in 1996-2000. Since 2000, 
olanzapine has been approved for schizophrenia and bipolar I disorder (adult).  
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Figure 2. 3. Mental diagnoses related with AAP visits 
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Figure 2. 4. Frequently used AAP agents 
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Table 2. 1. Baseline characteristics of pediatric ADHD visits* 
 
Baseline Characteristics 
AAP visits (N=3,763) Non AAP visits (N=27,738)  
p Value N % N % 
Age 
   Pre-school child (age 4-5)** 179 4.76 1,213 4.37 0.867 
   Elementary child (age 6-11)** 2,026 53.84 17,081 61.58 0.085 
   Adolescent (age 12-18)** 1,558 41.40 9,445 34.05 0.089 
Sex 
   Male 2,768 73.56 19,587 70.62 0.498 
   Female 995 26.44 8,151 29.38 0.498 
Race 
   White 2,948 78.34 22,427 80.85 0.449 
   Black 654 17.37 4,289 15.46 0.507 
   Other 162 4.30 1,021 3.68 0.744 
Region of residence 
   Northeast 726 19.28 4,876 17.58 0.681 
   Midwest 896 23.82 7,160 25.81 0.700 
   South 1,484 39.43 11,011 39.70 0.969 
   West 657 17.46 4,690 16.91 0.916 
Median household income in patient’s zip code 
   Quartile 1  1,086 28.85 5,886 21.22 0.160 
   Quartile 2 859 22.84 8,292 29.89 0.067 
   Quartile 3 792 21.05 6,106 22.01 0.837 
   Quartile 4 1,026 27.26 7,454 26.87 0.942 
Percent population with Bachelor’s degree or higher in patient’s zip code 
   Quartile 1 1,074 28.55 7,648 27.57 0.853 
   Quartile 2 859 27.22 8,292 22.52 0.181 
   Quartile 3 792 18.62 6,106 26.19 0.105 
   Quartile 4 1,026 25.61 7,454 23.71 0.672 
Metropolitan statistical area  
   No 487 12.93 5,542 19.98 0.248 
   Yes 3,277 87.07 22,195 80.02 0.248 
Payer source 
   Private 1,533 40.75 14,726 53.09 0.035 
   Medicaid 1,976 52.50 10,593 38.19 0.013 
   Self-pay 296 7.87 1,706 6.15 0.610 
   Other 1,690 5.45 204 6.09 0.800 
Mental health provider 
    No 1,103 94.79 26,635 96.02 0.341 
    Yes 196 5.21 1,103 3.98 0.341 
Attention deficit disorder with hyperactivity 
   No 132 41.24 4,040 44.75 0.010 
   Yes 3,632 58.76 23,698 55.25 0.010 
Number of non-AAP prescribed (different generic names) 
   0  322 8.56 3,417 12.32 0.138 
   1  747 19.86 13,180 47.52 <0.001 
   2 1,058 28.11 5,607 20.21 0.007 
   3 836 22.22 3,152 11.36  0.001 
   4+ 800 21.25 2,382 8.59 <0.001 
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Table 2. 1. Baseline characteristics of pediatric ADHD visits* - cont’d 
 
Baseline Characteristics 
AAP visits (N=3,763) Non AAP visits (N=27,738)  
p Value N % N % 
Comorbidities† 
   FDA approved indications 970 25.77 2,304 8.31 <0.001 
   Psychoses 321 8.53 547 1.97 <0.001 
   Neurotic disorder 466 12.39 1,316 4.75 0.001 
   Adjustment disorder 88 2.33 435 1.57 0.304 
   Disturbance 886 23.55 1,769 6.38 <0.001 
   Developmental disorder 177 4.70 799 2.88 0.358 
   Obesity 2 0.04 371 1.34 <0.001 
   Diabetes 7 0.18 4 0.01 0.008 
   Cardiovascular disease 0 0.00 10 0.04 0.611 
*Data are given as weighted count of visits and percentage. 
**These variables were tested as binary variables. That is, instead of testing as a single age variable 
with three categories, the three categories were tested individually as binary variables.   
†These variables are not mutually exclusive. 
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Table 2. 2. Predictors of atypical antipsychotic prescription 
Covariates Odds ratio 95% Confidence interval 
Age 
   Pre-school child (age 4-5) Reference  
   Elementary child (age 6-11) 0.86 0.35-2.09 
   Adolescent (age 12-18) 1.11 0.49-2.53 
Sex 
   Male Reference  
   Female 0.81 0.51-1.29 
Race 
   White Reference  
   Black 0.86 0.48-1.55 
   Others 2.05 0.77-5.43 
Region of residence 
   Northeast Reference  
   Midwest 0.84 0.40-1.75 
   West 0.84 0.38-1.84 
   South 0.90 0.43-1.89 
Median household income in patient’s zip code 
   Quartile 1  Reference  
   Quartile 2 0.65 0.39-1.10 
   Quartile 3 0.79 0.38-1.65 
   Quartile 4 0.93 0.39-2.24 
Percent population with Bachelor’s degree or higher in patient’s zip code 
   Quartile 1 Reference  
   Quartile 2 1.31 0.73-2.33 
   Quartile 3 0.77 0.31-1.88 
   Quartile 4 1.02 0.41-2.50 
Metropolitan statistical area  
   Yes Reference  
   No 0.52 0.21-1.30 
Payer source 
   Private Reference  
   Medicaid 1.66* 1.01-2.75 
   Self-pay 1.19 0.29-4.94 
   Other 1.08 0.38-3.09 
Mental health provider 
    No Reference  
    Yes 0.77 0.31-1.92 
Attention deficit disorder with hyperactivity 
   No Reference  
   Yes 3.00 0.75-11.93 
Number of non-AAP prescribed (different generic names) 
   0  Reference  
   1  0.94 0.58-1.52 
   2 2.60* 1.38-4.90 
   3 3.06* 1.48-6.32 
   4+ 4.48* 2.08-9.64 
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Table 2. 2. Predictors of atypical antipsychotic prescription – cont’d 
Covariates Odds ratio 95% Confidence interval 
Mental Comorbidities 
   FDA approved indications Reference  
   Psychoses 3.34* 1.35-8.26 
   Neurotic disorder 2.67* 1.27-5.61 
   Adjustment disorder 1.21 0.57-2.58 
   Disturbance 3.60* 1.94-6.69 
   Developmental disorder 1.81 0.71-4.63 
Physical Comorbidities‡   
   Obesity 0.03 0.57-0.19 
   Diabetes 14.21* 1.77-114.28 
   Cardiovascular disease dropped†  
†The variable of cardiovascular disease was dropped because it predicted no AAP use 
(AAP=0) perfectly.   
‡These variables are mutually exclusive. 
*Significant at 5% significance level. 
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Chapter 3: The Risk of Developing Type II Diabetes in Atypical Antipsychotic Users 
among Children and Adolescents  
 
A. Background 
 The increase in pediatric AAP use is concerning considering the potential risk of 
developing chronic conditions suggested by previous studies, such as obesity31,34,35,38-40 or 
type II diabetes (T2DM) in children and adolescents taking these drugs.45,46,57 While 
several post-marketing studies examined weight gain and obesity and provided solid 
support for the risk, the evidence regarding the risk of T2DM is still limited in younger 
populations. Although there are plausible mechanisms to support the hypothesized risk 
for T2DM, 58,59 several prior studies evaluating the relationship between AAP use and 
diabetes in children and adolescents failed to discriminate between type I and II DM46, 
thus resulting in an underestimation of the true effect.60 A recent study evaluated this 
specific AAPs-T2DM relationship, but the study population was restricted to a single 
state Medicaid population.57 These findings from a single state Medicaid program may 
not be generalizable to a broader population.55 Therefore, the purpose of this paper is to 
estimate the risk of developing T2DM for children and adolescents who are prescribed 
an AAP, using nationally representative health care claims data in the U.S. 
 
B. Materials and methods 
Data Source and Study Population 
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Through a new user design approach,61 we assembled a retrospective cohort of 
children and adolescents using enrollment files, medical and pharmacy claims data from 
the i3 Invision Data Mart (IVDM). These data contain information for a de-identified, 
nationally representative sample of 15 million commercially insured and Medicaid 
managed care patients. Dependents between the ages of 4 to 18 at index date (described 
below), who were continuously enrolled between January 1, 2007 and December 31, 
2009, were considered for this study.  
 
Exposure 
Our study compared an AAP user to a similar group of subjects with no 
exposure to AAP (non-users). Subjects were considered to be exposed to an AAP if they 
had at least one prescription for any of the available AAPs, which include aripiprazole, 
olanzapine, paliperidone, quetiapine, risperidone, and ziprasidone. AAP users were 
classified as incident or new users (AAP users, hereafter)  and included in the analysis if 
they met all of the following eligibility criteria: (1) initial dispensing date of an AAP 
(defined as the index date) was preceded by a minimum of six months of continuous 
enrollment in the health plan (i.e., pre-index period); (2) did not have prescriptions for 
typical antipsychotics during the six months of the pre-index period; (3) had no history 
of type I or type II diabetes during the six months pre-index period; (4) had evidence of 
resource utilization in the database (i.e., at least one claim of any type during the pre-
index period). This requirement was made to exclude individuals with multiple health 
insurance (i.e., a child whose parents hold multiple health insurance) and made claims 
47 
 
primarily to another plan other than the one used in this paper, thus to prevent 
misclassification due to out-of-insurance service utilization. For the comparison group of 
non-users, index dates were randomly assigned based on the distribution of time to 
AAP initiation after January 1, 2007 in the AAP treated group. With the randomly 
assigned index date, the same sample selection criteria described above for the AAP 
treated group (except for AAP prescription) were applied to the non-user group A flow 
diagram describing the identification process for the groups included in the analyses is 
depicted in Figure 3. 1. 
The follow-up time for each subject started on the index date and was extended 
until the earliest of (1) T2DM onset, or (2) the end of the study period. This approach 
was intended in order to emulate an intention-to-treat analysis similar to randomized 
controlled trials.  
 
Outcome 
The outcome of interest in our study was new-onset T2DM and was identified 
using medical and pharmacy claims and following the algorithm developed by Bobo et 
al. (2012).62 We used International Classification of Diseases, 9th Clinical Modification 
(ICD-9-CM) diagnosis codes (250; 250.0; 250.1; 250.2; 250.3; 250.9) and National Drug 
Codes (NDC) for anti-diabetic medications (insulin, insulin adjuncts, alpha-glucosidase 
inhibitor, amylin analogs, meglitinides, sulfonylureas, and thiazolidinediones) to 
identify diabetes-related medical/pharmacy care encounters. In order to classify a 
patient as having T2DM, we required (1) a hospital discharge with a primary diagnosis 
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code for T2DM as described above, or (2) a combination of at least 2 diabetes-related 
medical and/or pharmacy claims. When only prescription claims indicated diabetes, 
T2DM was further separated from type I diabetes by excluding those with an insulin 
prescription with no prescriptions for oral anti-diabetic medication. The date of onset for 
T2DM was determined as the date of the first medical/pharmacy care encounter related 
to T2DM. However, if a diabetes-related laboratory procedure (i.e., HbA1c, islet cell 
antibody test, insulin RIA, or metabolic panel) was performed within 30 days before the 
first diabetes-related medical/pharmacy care encounter, the date of the procedure was 
considered as the date of T2DM onset.  
 
Covariates 
To control for potential selection bias and confounding, non-users were matched 
to AAP users using the propensity score (PS) matching method. The PS for each resident 
was estimated through logistic regression as the probability of starting AAP treatment 
during our study period, based on their baseline characteristics. We used causal 
diagrams63,64 to select important covariates for inclusion in the logistic regression model; 
specifically, the following covariates were included: age, sex, race, geographic region, 
household income, the year of index date, and the health care utilization intensity and 
medical history during the pre-index period. Health care utilization intensity was 
measured by four variables: the number of hospitalizations, the number of emergency 
room (ER) visits, the number of outpatient services, and the number of filled 
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prescriptions with different generic names. Medical history was measured through other 
medications used (i.e., benzodiazepines and antidepressants), as well as comorbidities 
(pregnancy, obesity, and cardiovascular diseases).  
 
Analysis 
 Baseline characteristics of AAP users and non-users were compared and tested 
before and after PS matching using standardized differences.65,66 Using PS, up to four 
non-users were matched to every AAP new user. The propensity to receive an AAP was 
estimated through unconditional logistic regression and the greedy matching 
algorithm67 with calipers equal to 0.2 of the standard deviation of the logit of the 
propensity score was used for matching.68 
The rates of developing T2DM in the AAP-treated group and control group were 
estimated and compared using the Kaplan-Meier (KM) estimator. Cox proportional 
hazard regression was performed to estimate the risk of T2DM associated with AAP 
initiation. We regarded that the proportional hazards assumption was not violated 
because no evidence of interaction between AAP use and time was observed. (HR 0.75; 
P=0.223).  
 
C. Results 
Baseline characteristics of non-matched samples 
 A total of 403,345 children and adolescents met our inclusion criteria. Among 
those, 6,510 individuals were new AAP users. A majority of AAP users received 
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risperidone (n=2608; 40.1%), aripiprazole (n=2044; 31.4%) or quetiapine (n=1439, 22.1%). 
Relatively small proportion of AAP users received olanzapine (n=239, 3.7%), ziprasidone 
(n=168, 2.6%) or paliperidone (n=50, 0.8%). There were 38 (0.6%) individuals who 
received two AAP agents on the index date. Other baseline characteristics before 
matching are summarized in Table 3. 1. In the non-matched sample, AAP users were 
more likely to be adolescents (ages 12-18) and male than non-users. On average, the 
annual household income was lower for AAP users. Also, the AAP users showed a 
higher level of health care utilization during the six month pre-index period, with 
respect to the number of outpatient service visits, hospitalizations, ER visits, and filled 
prescriptions. The baseline comorbidities and drug use profiles also showed large 
differences between the two groups in several respects: AAP users evinced higher 
prevalence rates of obesity and cardiovascular disease. Also, they showed a higher rate 
of use for benzodiazepines or antidepressants.  
 
Calculation of propensity scores  
 The logistic regression model to evaluate AAP utilization is described in Table 3. 
2. The results indicate that older patients were more likely to receive an AAP. Female 
patients were less likely to receive an AAP compared to male patients. Also, western 
regions of the US were more likely to use an AAP compared to northeastern regions. 
Annual household income was significantly associated with AAP use: the propensity to 
receive an AAP decreased as the level of household income increased (Table 3. 2). The 
higher level of health care utilization measured in the number of outpatient service visits, 
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hospitalizations, and prescriptions significantly increased the propensity to receive an 
AAP. The c-statistic was 0.876, indicating a good predictive accuracy of the logistic 
regression model.  
 
Baseline characteristics of propensity score-matched sample 
 The final study sample after PS matching consisted of 6,236 incident AAP users 
and 22,080 non-users. The characteristics of matched samples are summarized in Table 2. 
1 (right). In this matched sample, AAP new users and matched non-users were balanced 
on all of the characteristics included in the PS model (standardized differences were 
smaller than 5%). Figure 3. 2 shows the kernel density estimates of the PS distribution 
between the two groups. The upper panel is depicting the distribution for the non-
matched sample, while the lower panel represents the matched sample showing the 
similarity between the two groups after PS matching. 
 
The Risk of Type II Diabetes 
The follow-up schedule was very similar between AAP user and non-user 
groups. In each group, the mean follow-up time was 1.3 (± 0.7) years with the minimum 
of 0 days and the maximum of 2.5 years. The total follow-up time was 8,161 person-
years in the AAP user group, and 28,792 person-years in the non-user group. During the 
follow-up, a total of 64 subjects developed T2DM, 27 in the AAP user group (33.1 cases 
per 10,000 person-years), and 37 in the non-user group (12.9 cases per 10,000 person-
years). 
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The rate of developing T2DM in the matched sample is represented using the 
Kaplan-Meier (KM) estimator (Figure 3. 3). The risk difference between two groups 
appeared at approximately 4 months after the index date, and it increased rapidly 
between 4 months and 6 months after the index date. After 6 months, the risk difference 
was almost constant until the end of the follow-up. The estimated risk of T2DM was 
twice higher in AAP users than non-users in the propensity score matched sample (HR 
2.18; 95% CI 1.45-3.29). 
 
D. Discussion 
 The purpose of this study was to examine the association between AAP initiation 
and T2DM in children and adolescents. We found that initiation of AAP medication 
increased the risk of developing T2DM about two-fold for those between the ages of 4 
and 18. While T2DM is known to develop slowly over months and years, the fact that 
noticeable risk differences between AAP-treated and comparison groups emerged 
between 4 and 6 months is striking. This result is in good agreement with a recent study 
published by Bobo and collaborators.57 They conducted a retrospective cohort study for 
children and youth, using Tennessee Medicaid health care claims data and reported a 
three-fold higher risk of T2DM imposed on antipsychotic medication users (both typical 
and atypical), compared to propensity score-matched users of other psychotropic drugs. 
Our observation on the probability of developing T2DM during the course of the follow-
up assessment (Kaplan-Meier Curve) is very similar to the result reported in this paper 
(Figure 3. 2). For example, at the 20 months (600 days) follow-up the probability of 
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T2DM is approximately 0.004 for treatment group, and 0.002 for control group in both 
studies. The fact that the point estimate of the hazard ratio reported by Bobo et al. is 
different from what we found in our study is likely due to differences in study design, 
specifically (1) different follow-up periods (longer for Bobo et al.) and/or (2) study 
population (Tennessee Medicaid vs US commercially insured). Another study 
previously conducted by Andrade et al. concerned the risk of diabetes associated with 
antipsychotic medication use in children and adolescents (ages of 5 to 18).46 They used a 
large diverse cohort from Health Maintenance Organization (HMO) databases and did 
not find a significant association between AAPs and diabetes in propensity score 
matched samples. One of the major differences between our study design and theirs was 
the inclusion of type I diabetes in study outcomes. However, a majority of diabetes 
patients in children are likely to be type I60 and the concerns about AAP adverse side 
effects are often associated with type II.58,59 Therefore, including type I diabetes in an 
outcome could have attenuated the risk of AAPs in their study.  
 In our propensity score matched cohort, a majority of individuals were 
adolescents with ages between 12 and 18 (61%), male (63%), and white (78%). 
Approximately 47% resided in the south region of the US and more than half of the 
sample belonged to households with an annual income greater than $60,000. During the 
6 month pre-index period, 86% have not been hospitalized and 98% have not visited ER. 
Also, 5% used benzodiazepine and 31% used antidepressant during the period. These 
factors could have affected results and need be taken into account when implementing 
the findings of this paper.   
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 It should be noted that the individuals who were identified as having new-onset 
T2DM are subject to a potential misclassification. The algorithm we adopted for this 
study was developed from a Tennessee Medicaid program, and it is possible that the 
algorithm did not effectively identify true T2DM cases in our database. If diabetes 
management or diabetes related claim filing process vary largely by the payer source or 
geographical regions, it may affect our conclusion about the impact of AAP on T2DM. 
Another limitation of our study is a relatively short follow-up. The longest possible 
follow-up period in this paper was 2.5 years and the follow-up term does not adequately 
capture the longer-term impact of AAPs on T2DM. Also, the small number of new-onset 
T2DM cases limited our ability to assess the differential impact of AAPs on different 
strata such as patient demographics and socioeconomic factors. 
 Having non-users as the comparison group might have overestimated the risk of 
T2DM for AAP users because AAP users are more likely to be monitored for T2DM than 
non-users. However, to minimize potential differences in monitoring between the two 
cohorts, we included non-users who had similar health conditions to AAP users during 
the pre-index period in the analysis. Moreover, that our study reports similar findings to 
previous studies supports the reliability of our study design.       
 Although it is not the primary interest for our paper, our logistic regression 
model revealed important factors associated with AAP use. (Table 3. 2) First, female 
patients were less likely to receive an AAP compared to male patients (OR 0.54; 95% CI 
0.51-0.57). This is consistent with the national trend, in which female patients are 
outnumbered by male patients in children and adolescent psychiatric services.69 
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Secondly, the propensity of a patient to receive an AAP decreased gradually as the 
household income increased. In other words, if a patient was from a high-income family, 
the patient was less likely to use an AAP. This finding has an important implication 
about the role of one’s socioeconomic status that affects the exposure to an AAP.  
 Our study adds strong evidence to the existing literature and overcomes some of 
the limitations of previous research. First, our report critically examined patients who 
possessed a commercial health care plan within the US, who were either commercially 
insured or enrolled in a Medicaid managed care plan. This consideration cannot be 
understated, because commercial insurance and Medicaid are the two largest payers of 
mental health services in the United States.70 Therefore, the findings of this paper can be 
more generalizable to a larger population. Second, we sought to avoid the bias by 
matching subjects based on their propensity to receive an AAP. Before matching, there 
was a considerable difference observed in baseline characteristics between AAP users 
and non-users. Atypical antipsychotic users were more likely to be obese and receive 
intense health care services such as hospitalizations and ER visits. (Table 3. 1, left) This 
suggests the presence of potential selection bias in the non-matched cohort, in which 
AAP users had inherently higher risk of developing a chronic illness including T2DM 
than non-users before they were exposed to an AAP. In our propensity score matched 
cohort, baseline characteristics were much similar between AAP users and non-users. 
 In conclusion, we found that children and adolescents who use an AAP 
medication had a two times higher risk of developing T2DM within 6 months of 
initiating medication when compared to propensity score matched non-users from 
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nationally representative health care claims in the U.S. This raises questions about 
continued AAP use in children and adolescents. Considering that T2DM is a chronic 
condition that may persist the rest of a person’s life, its risk that is imposed on children 
and adolescents could outweigh the benefit of AAP therapy in some patients.    
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Figure 3. 1. Sample selection flowchart 
 
 
 
 
Patients (4 ≤ Age ≤ 18) who were continuously enrolled for three years 
N = 669,253 
Excluded: 
1. Less than 6 months between enrollment and the 
initial atypical antipsychotic dispensing date 
(N=9,163) 
2. No claims made during 6 month pre-index period 
(N=254,737)  
3. Having conventional antipsychotics prescription 
during 6 month pre-index period. (N=358)  
4. Having type I or II diabetes (diagnosis, 
prescriptions) during 6 month pre-index period. 
(N=1,650) 
 
AAP users before matching 
N = 6,510 
Non-users before matching  
N = 396,835 
Study population before propensity score matching  
N = 403,345 
AAP users after matching 
N = 6,236 
Non-users after matching 
N = 22,080 
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Table 3. 1. Baseline characteristics 
 
 
Baseline 
Characteristics 
Before Matching After Matching 
AAP users 
(N=6,510) 
Non-users 
(N=396,835) 
 
 
d* 
AAP users 
(N=6,236) 
Non-users      
(N=22,080) 
 
 
d* n % n % n % n % 
Age 
   4-5  246  3.8  57,793  14.6 0.380  245  3.9  1,056  4.8 0.018 
   6-11  2,023  31.1  164,612  41.5 0.218  1,994  32.0  7,721  35.0 0.024 
  12-18  4,241  65.2  174,430  44.0 0.436  3,997  64.1  13,303  60.3 0.031 
Sex 
   Male  3,978  61.1  203,505  51.3 0.199  3,802  61.0  13,901  63.0 0.030 
   Female  2,532  38.9  193,330  48.7 0.199  2,434  39.0  8,179  37.0 0.030 
Race 
   White  5,126  78.7  297,885  75.1 0.087  4,910  78.7  17,274  78.2 0.008 
   Black  288  4.4  15,199  3.8 0.030  275  4.4  976  4.4 0.001 
   Hispanic  431  6.6  34,211  8.6 0.075  414  6.6  1,494  6.8 0.001 
   Others  617  9.5  46,812  11.8 0.075  592  9.5  2,087  9.5 0.003 
Region of residence 
   Northeast  712  10.9  48,113  12.1 0.037  690  11.1  2,357  10.7 0.015 
   Midwest  1,731  26.6  102,996  26.0 0.014  1,647  26.4  5,826  26.4 0.007 
   South  3,074  47.2  190,671  48.1 0.017  2,944  47.2  10,430  47.2 0.006 
   West  993  15.3  54,942  13.9 0.040  955  15.3  3,464  15.7 0.013 
Annual household income 
   ≤ $29,999  207  3.2  10,152  2.6 0.037  193  3.1  764  3.5 0.020 
   $30,000-39,999  364  5.6  17,593  4.4 0.053  348  5.6  1,350  6.1 0.017 
   $40,000-49,999  585  9.0  32,271  8.1 0.031  558  9.0  1,974  8.9 0.004 
   $50,000-59,999  596  9.2  35,877  9.0 0.004  570  9.1  2,102  9.5 0.010 
   $60,000-74,999  790  12.1  51,644  13.0 0.027  757  12.1  2,702  12.2 0.001 
   $75,000-99,999  1,170  18.0  81,702  20.6 0.066  1,133  18.2  3,880  17.6 0.013 
   ≥ $100,000  1,563  24.0  115,304  29.1 0.114  1,520  24.4  5,171  23.4 0.024 
Number of outpatient service visits 
   0-5  2,357  36.2  330,942  83.4 1.098  2,353  37.7  8,858  40.1 0.041 
   6+  4,153  63.8  65,893  16.6 1.098  3,883  62.3  13,222  59.9 0.041 
Number of drugs prescribed (difference generic name drugs) 
   0-3   3,045  46.8  326,225  82.2 0.797  3,012  48.3  11,513  52.1 0.001 
   4+  3,465  53.2  70,610  17.8 0.797  3,224  51.7  10,567  47.9 0.001 
Number of hospitalizations 
   0  5,214  80.1  392,254  98.9 0.642  5,202  83.4  19,315  87.5 0.007 
   1-3  1,273  19.6  4,500  1.1 0.635  1,012  16.2  2,721  12.3 0.006 
   4+  23  0.4  81  0.0 0.077  22  0.4  44  0.2 0.011 
Number of ER visits 
   0  6,413  98.5  393,944  99.3 0.073  6,145  98.5  21,811  98.8 0.018 
   1+  97  1.5  2,891  0.7 0.073  91  1.5  269  1.2 0.018 
Baseline comorbidities and drug use 
   Obesity  157  2.4  4,086  1.0 0.106  150  2.4  458  2.1 0.009 
   Cardiovascular  259  4.0  4,504  1.1 0.181  240  3.9  714  3.2 0.009 
   Pregnancy  9  0.1  336  0.1 0.016  9  0.1  30  0.1 0.001 
   Benzodiazepine  460  7.1  2,764  0.7 0.334  413  6.6  976  4.4 0.025 
   Antidepressant   2,648  40.7  9,439  2.4 1.053  2,374  38.1  6,409  29.0 0.033 
*Standardized Difference. 
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Table 3. 2. Propensity score model of receiving an atypical antipsychotic medication 
Confounder OR 95% CI 
Age 
   4-5 Reference  
   6-11 2.68* 2.34-3.01 
  12-18 3.26* 0.85-3.73 
Sex 
   Male Reference  
   Female 0.54* 0.51-0.57 
Race 
   White Reference  
   Black 1.25* 1.10-1.43 
   Hispanic 0.86* 0.77-0.95 
   Others 0.88* 0.80-0.97 
Region of residence 
   Northeast Reference  
   Midwest 0.99 0.91-1.10 
   West 1.07* 1.23-1.52 
   South 1.07 0.98-1.17 
Annual household income 
   ≤ $29,999 Reference  
   $30,000-39,999 1.01 0.89-1.15 
   $40,000-49,999 0.80* 0.72-0.89 
   $50,000-59,999 0.74* 0.66-0.82 
   $60,000-74,999 0.63* 0.57-0.69 
   $75,000-99,999 0.58* 0.53-0.63 
   ≥ $100,000 0.48* 0.44-0.52 
Number of outpatient visits 
    0-5 Reference  
   6+ 3.84* 3.61-4.08 
Number of drugs prescribed (different generic name drugs) 
   0-3  Reference  
   4+ 2.04* 1.93-2.17 
Number of hospitalizations 
   0 Reference  
   1-3 5.94* 5.45-6.47 
   4+ 3.10* 1.78-5.40 
Number of ER visits 
   0 Reference  
   1+ 0.77* 0.60-0.98 
Baseline comorbidities and drug use 
   Obesity 1.03 0.85-1.24 
   Cardiovascular disease 0.79* 0.68-0.93 
   Pregnancy 0.31* 0.15-0.65 
   Benzodiazepine use 1.95* 1.71-2.22 
   Antidepressant use 12.01* 11.28-12.80 
*Significant at 5% significance level 
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Figure 3. 2. Propensity score distribution 
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Figure 3. 3. Kaplan-Meier curve estimating the probability of type II diabetes 
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Chapter 4: A decision analysis of atypical antipsychotics treatment in the stimulant 
failed ADHD children and adolescents.  
 
A. Background 
Attention-deficit/hyperactivity disorder (ADHD) is the most common 
neurobehavioral disorder of childhood, characterized by having trouble paying 
attention, not being able to control impulsive behaviors, and being overly active.11 Those 
with ADHD may experience academic underachievement, troublesome interpersonal 
relationship development, and low self-esteem. While medication therapy and/or 
behavior therapy are recommended for the ADHD treatment, medication therapy has 
been reported as the most cost-effective choice.71 Medication therapy usually initiates 
with stimulants such as amphetamine derivatives (e.g., Adderall), which are FDA-
approved stimulant medications for ADHD. Although the symptoms are successfully 
managed with stimulants in most ADHD patients for the short term (6-10 weeks),19-21 an 
alternative medication regimen is often considered due to the adverse side effects, 
tolerance development or lack of symptom improvement.24 Some of selective 
norepinephrine reuptake inhibitor (atomoxetine) and selective α2-adrenergic agonists 
(clonidine, guanfacine) are non-stimulant ADHD medications approved by FDA and 
they are recommended as an alternative to stimulants.11  
However, a growing number of ADHD children and adolescents are prescribed 
with atypical antipsychotics (AAPs),8,22,23 although it is not yet justified with evidence. 
Findings about the clinical effectiveness of AAPs in ADHD are mixed with different 
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conclusions. Moreover, several adverse side effects were reported as being associated 
with AAPs, which include weight gain,34,38,40 type II diabetes,28,46,57 and QTc interval 
prolongation.72,73 Therefore, the expected health outcomes based on clinical drug 
effectiveness and the risk of adverse effects need to be estimated for AAPs before 
considering them as a stimulant alternative. This is also true for other non-stimulant 
medications as they have risks of several adverse effects (e.g., high blood pressure74 
and/or suicidal ideation75 in atomoxetine users, bradycardia76,77 in clonidine or 
guanfacine users). Then, health care providers and patients will be able to compare the 
expected health outcomes between strategies and take that into account when they make 
decisions about their treatment strategy.  
Furthermore, in addition to the expected health outcome, decision-making 
depends heavily on health care costs as well. Evaluating the combination of health 
outcomes and costs, which is referred to as “cost-effectiveness”, is one of the most 
critical elements when choosing the appropriate therapy among multiple strategies.   
Therefore, the aims of this paper are: (1) to estimate the expected health 
outcomes of AAPs and other non-stimulant ADHD medications based on trade-offs 
between clinical effectiveness and adverse effects and (2) to evaluate cost-effectiveness 
of AAPs compared to other non-stimulant ADHD medications. Both aims target the 
stimulant-failed ADHD children and adolescents.  
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B. Material and methods 
We conducted a decision analysis estimating trade-offs between individual level 
health benefits and risks in treating ADHD children and adolescents who failed the 
initial stimulant treatment and require non-stimulant subsequent pharmacotherapy. The 
analysis is intended to address whether atypical antipsychotics (AAPs) should be 
recommended for ADHD children and adolescents, compared to other alternatives to 
stimulants.  
 
The Decision Tree 
Most of ADHD patients who choose to receive medication therapy start their 
treatment with a stimulant. However, due to a lack of effectiveness or tolerance 
development, a subset of the patients cannot be treated with stimulants anymore and 
this situation is where we intend our study to be implemented. In other words, the 
starting point of the decision tree is where the prescriber and patient seek an alternative 
treatment strategy as a replacement of stimulant, among three medication choices: (1) 
AAP (aripiprazole, olanzapine, paliperidone, quetiapine, risperidone, ziprasidone) (2) 
selective norepinephrine reuptake inhibitor (atomoxetine), and (3) alpha-2 adrenergic 
agonists (clonidine, guanfacine). (Figure 4. 1) The square box at the start of the decision 
tree is a decision node and represents the decision to be made by the prescriber and 
patient. The branches coming out of the decision node represent the range of possible 
pathways that could result from different choices. Each pathway consists of a series of 
branches that leads to particular events that might be experienced by a patient. In this 
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study, those events are ADHD symptoms, weight gain, type II diabetes, suicidal 
ideation, and cardiovascular events such as QTc interval prolongation, high blood 
pressure, or bradycardia. Since it is not certain which events a patient will experience, 
such uncertain events are defined by circular nodes (chance nodes). The endpoint of the 
decision analysis was 1 year of treatment with 28 different pathways. In this model, the 
expected health outcomes are estimated using quality-adjusted life years (QALYs) that 
are weighed on a basis of the probabilities of clinical drug effectiveness and side effects.      
 
Estimating Probabilities and Quality-Adjusted Life Years (QALYs) 
Probability estimates were derived from literature review. (Table 4. 1) Based on a 
systematic search of the literature, we chose a methodologically well-designed study to 
obtain a baseline estimate. If multiple studies exist for one estimate, the average was 
calculated.78 The Supplementary Appendix provides the conversion process used to 
create probabilities that have the minimum value of 0 and the maximum value of 1.  
For the baseline probability estimate of AAPs’ effectiveness in ADHD, three 
randomized controlled trial (RCT) papers were used.79-81 Although those studies are 
restricted to risperidone79,80 and aripiprazole81 only, we assumed that other AAP agents 
will have a similar effectiveness since they share the similar mechanism of action.  
The adverse side effects associated with AAP including weight gain, type II 
diabetes, and QTc interval prolongation were examined. The baseline probability of 
weight gain was obtained from three cohort studies in which AAP users were compared 
with non-users.34,38,40 For type II diabetes, we based our assumptions on two 
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observational studies.46,57 For the AAP-associated cardiovascular events, we obtained the 
baseline probability of QTc interval prolongation by averaging the findings of a RCT 
conducted by Hough et al.,72 and a case-control study conducted by Correll et al.73  
We obtained our assumptions about the drug effectiveness of atomoxetine from 
RCTs.82-86 The average estimate was 0.62 with a small variation. For the potential side 
effects of atomoxetine, there is a black-box warning on atomoxetine concerning suicidal 
ideation. The baseline probability of experiencing suicidal ideation in pediatric patients 
was estimated to be 0.0037 from a meta-analysis conducted by Bangs et al.75 As another 
adverse side effect of atomoxetine, the baseline probability of having increased diastolic 
blood pressure was estimated from a RCT conducted by Wernicke et al.74      
The baseline probability of the effectiveness of clonidine or guanfacine (hereafter 
referred to as clonidine/guanfacine) was obtained from three RCTs.76,87,88 Similar to 
atomoxetine studies, the average estimates was 0.63 with a small variation in 
clonidine/guanfacine. One of the major adverse side effects in those medications, 
bradycardia, was examined in two RCTs and the average estimate was used as the 
baseline probability.76,77   
In order to calculate QALYs for each pathway in the decision tree as the health 
outcome, we derived QALY weights from a literature review (Table 4. 2). Papers that 
were chosen to estimate QALY weights for ADHD, overweight/obese, diabetes, and 
cardiovascular events (QTc interval elongation, increased diastolic blood pressure, and 
bradycardia) were consistent in using PedsQLTM 4.0 (Pediatric Quality of Life 
inventoryTM Version 4.0) as the measurement instrument.89-92 The PedsQL is a scale 
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designed to measure quality of life in the pediatric population. However, to our 
knowledge, the QALY weights for suicidal ideation in the pediatric population have not 
been published, therefore, we chose a study conducted by Goldney et al., in which a 
QALY weight was estimated in those age 15 and over using the Assessment of Quality 
of Life (AQoL) instrument.93  
The papers we used to estimate QALYs in our analyses also reported the average 
QALY weights from a healthy population as a control. Theoretically, a perfect health 
state has the QALY weight of 1 but the average QALY weights of the healthy population 
from papers were less than 1. In order to capture the QALY weight contributed to the 
conditions we are interested in, the QALY weights of health outcomes were rescaled to 
reflect the relative difference from the perfect health state which has the value of 1. This 
process involves taking the difference between the QALY weights of the study 
population and the healthy population, and use the difference as the disutility relative to 
the perfect health state.    
Using QALY weights derived from literature, QALYs over one year of ADHD 
treatment were estimated. Health outcomes beyond this time were not estimated due to 
the short-term nature of better quality trials. Also, it was assumed that health benefits 
and adverse side effects seen within ~6 weeks after initial treatment will persist for a 
year as medication treatment continues. More specifically, this is applied to drug 
effectiveness, QTc interval prolongation, increased diastolic blood pressure, suicidal 
ideation and bradycardia. For the AAP-associated weight gain, since the significant 
weight gain was not observed in 6-week trial79 but observed in 12-week trial40, we 
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assumed that the notable weight gain would take effect approximately between 6 weeks 
and 3 months after initiating AAP treatment and persist throughout the treatment 
period. For the AAP-associated type II diabetes, it was assumed to occur within 6 
months after initiation of therapy, as reported in several children/adolescent treatment 
trials.94,95  
We were not able to find studies that measured health-related quality of life 
specifically associated with QTc interval prolongation, high blood pressure, and 
bradycardia in the pediatric population. Instead, we used a study conducted by Uzrak et 
al.(2008) in which quality of life scores were stratified by disease severity. They 
categorized disease severity as follows: 1, mild cardiovascular disease (CVD) requiring 
no therapy or effectively treated nonoperatively (cathether therapy); 2, moderate CVD 
requiring no therapy or surgically corrected (curative); 3, surgically treated CVD (≥1 
procedure) with significant residua or need for additional surgery; 4, complex or severe 
CVD, uncorrectable or palliated (includes single ventricle). We took the average score of 
severity 1 and 2 as the baseline estimate of QTc interval prolongation, high blood 
pressure, and bradycardia, since those conditions may not require any medical 
procedure in some cases but they are risk factors of other heart diseases.  
 
Calculating the tree 
We used the ‘rolling back’ process to calculate the decision tree. This involves 
working from the right-hand side of the tree towards left, calculating expected QALYs at 
each chance node, until arriving at the index decision.  
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Cost Estimation 
Expected costs were derived from a retrospective cohort study conducted by 
Sikirica et al.24 In their study, ADHD children and adolescents who received non-
stimulant therapy were followed for one or more years after the initiation of the 
treatment and total health care costs accrued to the patients were estimated in AAP 
users and non-AAP users (They grouped atmoxetine users and clonidine/guanfacine 
users together as non-AAP users). In order to control for potential selection bias, Sikirica 
et al. matched the two groups using patient demographics, geographic region, year of 
therapy initiation, stimulant use history, comorbidity, all-cause and mental health-
related medical care utilization and pharmacy costs during the 6-month pre-index 
period. Also, they excluded patients who have any medical claims associated with 
conditions that are frequently treated with AAPs (schizophrenia, bipolar disorder, etc.) 
to increase the likelihood that patients received AAPs for ADHD and not other 
indications. The result indicated that the average annual total health care cost for AAP 
users were $6,934, while it was $4,748 for non-AAP users (P<0.001). For non-AAP users, 
we assumed that the expected costs of atomoxetine and guanfacine/clonidine would not 
be significantly different because they have the close estimates of the average monthly 
drug costs ($239 vs. $212, respectively)96, drug effectiveness (0.63 vs. 0.63, respectively), 
and health outcomes (0.94 vs. 0.95, respectively).  
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Sensitivity Analyses  
Multiple sensitivity analyses were conducted to evaluate the robustness of our 
conclusion. First, we conducted the one-way deterministic sensitivity analysis for 
estimating expected QALYs. In the analysis, the expected QALYs were examined as one 
variable varies across the plausible range (Tables 4. 1 and 4. 2), while holding other 
variables constant. Second, a Monte Carlo probabilistic sensitivity analysis was 
performed to examine the cost-effectiveness of three strategies in 50,000 simulations. The 
beta distribution was used for probabilities and QALYs, and the gamma distribution 
was used for costs.viii  
 
C. Results 
Base Case Analysis  
Over one year of ADHD medication treatment, the highest QALY was estimated 
for clonidine/guanfacine (expected QALY 0.95), followed by atomoxetine (expected 
QALY 0.94). (Table 4. 3, left)  Atypical antipsychotics yielded the lowest health outcome 
with the expected QALY of 0.84.  
In the cost-effectiveness analysis, the strategy of AAPs was “dominated” as it 
was less effective and costed more than other two strategies. Compared to 
clonidine/guanfacine, AAPs provided a lower QALY (0.11 QALY lost) at an additional 
viii The beta distribution restricts values from 0 to 1 and allows various shapes, 
and the gamma distribution restricts values zero or nonnegative and takes a right 
skewed form. 
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cost of $2,186 on average. Compared to atomoxetine, AAPs resulted in 0.10 QALY lost at 
an additional cost of $2,186.  
 
One-Way Sensitivity Analyses for Expected Health Outcomes  
One-way deterministic sensitivity analyses indicated that our finding from the 
base case analysis about AAPs as the less effective strategy was robust in all variables. 
Also, we identified variables with the most influence on incremental QALYs from the 
analyses. The result of comparing AAPs to clonidine/guanfacine is shown in a tornado 
diagram (Figure 4. 2). The QALYs of having untreated ADHD (i.e., medication is not 
effective) had the most impact on the change in health outcomes. The QALYs of having 
overweight/obesity were also shown to have a comparably large impact. Among 
probabilities, the probability of AAP effectiveness was the most influential variable, 
followed by the probability of having AAP associated type II diabetes. The comparison 
between AAPs and atomoxetine lead to the same conclusions; in which the QALYs of 
having untreated ADHD and having overweight/obesity, followed by the probability of 
AAP effectiveness, were the most influential variables. 
 
Probabilistic Sensitivity Analyses for Cost-Effectiveness 
 The simulated cost-effectiveness derived from the Monte Carlo probabilistic 
sensitivity analysis is presented with a scatter plot in Figure 4. 3. The closer a point is to 
the right-bottom corner of the chart, the more cost-effective it is. It is observed that the 
cost-effectiveness points of clonidine/guanfacine and atomoxetine are relatively more 
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concentrated around the right-bottom corner of the chart than AAPs. The cost-
effectiveness points of AAPs are spread over a larger area, indicating the higher 
frequency of being less cost-effective than other strategies.  
The average costs and expected QALYs from the base case analysis were 
compared to the ones generated from the probabilistic sensitivity analysis (Table 4. 3, 
right). The average cost-effectiveness ratio is smaller in the probabilistic sensitivity 
analysis compared to the base case analysis for AAPs (Table 4. 3, left), while it is larger 
in the probabilistic sensitivity for other strategies. However, the conclusion about AAPs 
being the dominated strategy is consistent in both analyses.  
 
D. Discussion 
The aims of the study were to: (1) estimate expected QALYs for non-stimulant 
medications in ADHD children and adolescents who have failed stimulants and (2) 
examine whether atypical antipsychotics (AAPs) should be recommended for ADHD 
children and adolescents as a cost-effective strategy, compared to other alternatives of 
stimulants. We developed a decision tree with the probabilities and QALYs of events 
followed by a strategy. Our decision analysis showed that AAPs lead to the lower 
expected QALYs than other strategies. Also, AAPs were not a favored choice for the 
stimulant-failed ADHD pediatric population with respect to cost-effectiveness and 
should not be recommended over other strategies, since it is less effective and costs more. 
This is depicted on the cost-effectiveness plane, as drawn in Figure 4. 4, where point A 
represents the AAP pharmacotherapy. The incremental ratio, compared to other 
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strategies (O), is OA. The “northwest” quadrant of the cost-effectiveness plane for which 
cost is increasing and quality is decreasing (“dominated”) is where the AAP 
pharmacotherapy is located. It is generally uncontroversial to reject such strategies, and 
therefore, we did not present an incremental cost-effectiveness ratio (ICER), although it 
is typically shown in many cost-effective analyses. 
In our decision tree model, the option of “no treatment” was not included 
because we assumed that the decision about whether a patient will receive the 
pharmacotherapy or not occurs before they initiate a stimulant treatment. Once failed 
with stimulant, the patient would seek alternative medications to treat ADHD based on 
the prior decision. However, it is possible that the patient and his/her prescriber 
consider no treatment when they make a decision after the stimulant failure. If this is the 
case, the conclusions of this paper may not be applicable, depending on the costs and 
expected health outcomes of not treating ADHD.   
The findings of this paper are best implemented in treating ADHD children and 
adolescents who do not have comorbid mental disorders for which AAPs are frequently 
prescribed, such as schizophrenia, bipolar disorder, or autism spectrum disorders. The 
estimated effectiveness of medications in our decision model is from clinical trials 
measuring the drug effectiveness on ADHD only. Therefore, the result could be different 
when another comorbid mental disorder is present. 
Also, we used the QALY of overweight/obesity and the probability of weight 
gain when estimating the expected health outcomes in the analyses. However, one 
should note that the weight gain may not necessarily result in overweight or obesity. 
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Considering our tornado diagram identifying the QALYs of overweight/obesity as the 
second most influential variable on the change in health outcome (Figure 4. 3), the 
expected health outcomes in AAPs could have been underestimated.  
When implementing the conclusions of this paper, our assumption that the 
health care costs of atomoxetine treatment were not significantly different from that of 
clonidine/guanfacine should be considered as a study limitation. For example, although 
our analyses suggested that the most cost-effective choice of stimulant alternative 
pharmacotherapy was clonidine/guanfacine over atomoxetine, the conclusion could be 
changed depending on the costs associated with each strategy, as the price differs by 
manufacturers (brand name drugs vs. generic drugs) and the formulation of the drug 
(extended release vs. immediate release). The rank of cost-effectiveness could be easily 
affected by the costs, because the expected health outcomes of clonidine/guanfacine and 
atomoxetine are similar (expected QALYs 0.95 vs. 0.94, respectively). The primary aim of 
the study was to evaluate the cost-effectiveness of AAP compared to other alternatives, 
and the decision making between the two non-AAP medications needs further 
specification.    
Another study limitation was the inclusion of type I diabetes when estimating 
QALY weights for AAP associated side effects. We based our assumption about QALY 
weights for type II diabetes on the study conducted by Varni et al., in which the quality 
of life for the both of type I and type II diabetes pediatric patients were assessed. It is 
possible that the quality of life for type I diabetes patients is inherently different from 
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type II diabetes patients, and the estimated QALY in this paper may not reflect the true 
value of type II diabetes.  
Clearly, the side effects associated with each strategy is not limited to the ones in 
the decision model. Some side effects associated with taking medications such as 
headache, nausea, vomiting, fatigue, dizziness, etc., were omitted because they are likely 
to be common in all strategies and the probabilities and impact on quality of life would 
be cancelled out during the analyses. However, side effects that are not included in the 
model but significantly affect expected health outcomes could draw different 
conclusions. For example, we used QTc interval prolongation as an AAP associated side 
effect, but the risk of other cardiovascular events including ischemic/pulmonary heart 
disease, arrhythmias and cardiomegaly was reported by McIntyre et al. They examined 
AAP-related cardiovascular events in children and adolescents at two levels of 
comparison: the primary comparison was performed between AAP users and non-users 
and secondary comparison was performed between single AAP users and multiple AAP 
users. We did not use their result for two reasons: (1) in the primary comparison, the 
confounders adjusted in the analysis were limited to age (≤ 12 years or ≥ 13 years), sex 
(male or female), and ethnicity (African American or other). The level of confounder 
adjustment is too weak to conclude a causal relationship between an AAP and 
cardiovascular events since AAP users are likely to be sicker than the untreated control 
group and cardiovascular events occurred in AAP users might not have been caused by 
an AAP. (2) While it is more appropriate to assume that our study population has not 
been treated with AAPs yet, they compared multiple AAP users to single AAP users in 
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the secondary comparison. However, it is possible that an AAP causes other 
cardiovascular events in addition to QTc interval prolongation and the expected health 
outcome could have been underestimated in this paper.   
In the policy decision making process, benefit-cost analysis may lead to a 
substantially different ranking of alternatives than cost-effectiveness analysis. While 
cost-effectiveness analysis look for cost-saving alternatives given an equivalent outcome, 
benefit-cost analysis focuses more on options that have the highest magnitude of net 
benefits. For instance, it is possible that a therapeutic choice with a higher net health 
benefit may not be preferred by cost-effectiveness analysis due to its high costs. Such 
difference in decision making perspective ultimately leads our next step to using 
willingness to pay measures. Since the money value that people place on health 
improvement is usually not observable, health services researchers have been using 
contingent valuation in which subjects are asked how much they are willing to pay for a 
health change in a hypothetical market setting. By replacing our health outcomes 
measured in utility to willingness to pay, a decision can be made based on the 
magnitude of net benefit and it may affect our recommendations about AAP use.  
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Figure 4. 1. Structure of the decision tree 
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Table 4. 1. Probability estimates 
Variable Baseline Variation range References 
  Low High  
Atypical antipsychotic     
Effectiveness 0.22 0 0.65 79-81 
Weight gain 0.7 0.65 0.8 34, 38, 40  
Type II diabetes 0.38 0 0.84 46, 58 
QTc interval prolongation 0.53 0 0.97 48, 73 
Atomoxetine     
Effectiveness 0.63 0.6 0.64 82-86 
Increased blood pressure 0.56 0 0.88 74 
Suicidal ideation 0.0037 0.0007 0.0044 75 
Clonodine/guanfacine     
Effectiveness 0.63 0.6 0.65 76, 87, 88 
Bradycardia 0.59 0.17 0.85 76, 77 
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Table 4. 2. Utility estimates 
Variable Baseline Variation range References 
  Low High  
Untreated ADHD  0.8673 0.5583 1 89 
Overweight/obese 0.9249 0.74485 1 90 
Diabetes 0.9847 0.92855 1 91 
QTc interval prolongation 0.9913 0.727 1 92 
High blood pressure 0.9913 0.727 1 92 
Bradycardia 0.9913 0.727 1 92 
Suicidal ideation 0.6156 0.4194 0.8118 93 
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Figure 4. 2. Tornado Diagram at AAPs vs. clonidine/guanfacine 
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Figure 4. 3. Cost-effectiveness scatter plot 
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Figure 4. 4. Cost-effectiveness plane 
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E. Supplementary Appendix 
This section provides supplementary material for the primary paper, including a more 
detailed presentation of several methodologic points. They should be read in 
conjunction with the primary paper.  
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Standardizing probabilities from different forms presented in literature 
 Probabilities of events in our decision tree were obtained in various forms from 
the literature. One of the typical ways of presenting the effectiveness/safety of a drug in 
a randomized control trial (RCT) is to use a two by two table. Also, many RCTs report 
effect size, which is calculated as the difference between the treatment group mean and 
the control group mean divided by pooled standard deviation (i.e., effect size = 
(treatment mean – control mean)/pooled SD). However, these are rarely used in 
observational studies. For example, studies that assessed antipsychotic agent associated 
weight gain reported the average change in body weights with standard deviation. In 
order to convert the different forms of probabilities into a standardized probability that 
takes 0 as the lowest possible value and 1 as the highest possible value, we used 
following methods.  
a. Calculating the standardized probability from two by two table.97 
The effectiveness/safety of a drug can be expressed using two by two table in a 
RCT. For example, following table is based on the result of RCT conducted by 
Daviss et al. (2008).77  
 Bradycardia No Bradycardia 
Clonidine-treated (n=31) 7 24 
Placebo (n=30) 1 29 
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They reported that the probability of having bradycardia in clonidine treated 
children was 22.6% (7/31*100 = 22.6%) and the probability of having bradycardia 
in placebo group was 3.3% (1/30*100 = 3.3%). The probability of clonidine-
associated bradycardia is calculated as the proportionate increase in the 
probability of bradycardia resulting from clonidine treatment, which is equal to 
0.854 = (0.226-0.033)/0.226. 
b. Calculating the standardized probability from effect size.98 
The effect size is defined as the difference between the mean outcomes for 
treatment and control groups in standard deviation units. Tickle-degnen (2001) 
argues that because the effect size is a standard normal deviate, we can assume a 
normal distribution to describe the variation of individuals’ responses around 
the average outcomes.98 For example, if the effect size is 0.65 as shown in the 
guanfacine RCT study conducted by Sallee et al. (2012), the probability of 
effectiveness is simply the area under the standard normal curve at 0.65, which is 
equal to 0.627.  
c.  Calculating the standardized probability from the change in body weight. 
The effect size of a drug with respect to weight gain is calculated based on the 
reported body weight changes of the treatment and control groups. Once the 
effect size is estimated, the standardized probability is obtained using the 
standard normal table.98  
d. Calculating the standardized probability from hazard ratio. 99 
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The hazard ratio is equivalent to the odds that a patient in the treatment group 
reaches the endpoint first.99 For example, the probability of developing type II 
diabetes first can be derived from the odds of developing type II diabetes first; 
which is the probability of developing type II diabetes first divided by the 
probability of not developing first:  
Hazard ratio (HR) = odds = P/(1 - P); 
P = HR/(1 + HR) 
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Chapter 5: Comparative health care cost and utilization in stimulant-treated ADHD 
patients  
 
A. Background 
In chapter 4, the expected health outcome and cost-effectiveness of AAPs were 
assessed in hypothetical ADHD patients who were previously treated with a stimulant 
and needed a subsequent pharmacotherapy. One of the study limitations was that I 
relied on a single original study article when obtaining the health care cost estimates. 
Because the study setting is particularly restricted to post-stimulant therapy, to the best 
of our knowledge, a study estimating additional costs accrued to AAP users was not 
published until 2013.24 Also, previous studies concerning pediatric AAP use have 
focused more on a clinical perspective, such as risks of developing chronic conditions 
including obesity31,34,35,38-40 or type II diabetes (T2DM).45,46,57  However, much more 
attention needs to be paid to the economic perspective, because a large proportion of 
pediatric AAP use is not evidence-based (i.e., ADHD) and potentially causes an overuse 
of healthcare resources. Therefore, the purpose of this chapter is to conduct an original 
study that compares resource utilization and costs between AAP users and non-AAP 
users in stimulant-treated ADHD children and adolescents. 
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B. Materials and methods 
Data Source and Study Population 
Through a new user design approach,61 I assembled a retrospective cohort of 4- 
to 24-year-old members using enrollment files, medical and pharmacy claims data from 
the i3 Invision Data Mart (IVDM). These data contain information for a de-identified, 
nationally representative sample of 15 million commercially insured and Medicaid 
managed care patients. Members between the ages of 4 to 24 at index date (described 
below), who had one or more medical claims with a primary diagnosis of ADHD 
between January 1, 2007 and December 31, 2009, were considered for this study. The 
diagnosis of ADHD was identified using the ICD-9-CM codes of 314.00 (attention-deficit 
disorder without hyperactivity) and 314.01 (attention-deficit disorder with 
hyperactivity). Subjects were also required to have made one or more claims for a 
stimulant prescription. The stimulant prescription was identified using NDCs which 
corresponded to a generic drug name including dexmethylphenidate, mixed 
amphetamine salts, methylphenidate, lisdexamfetamine, or dextroamphetamine.   
 
Exposure 
My study compared an AAP user to a non-AAP user. Subjects were considered 
to be exposed to an AAP if they had at least one prescription for any of the available 
AAPs, which include aripiprazole, olanzapine, paliperidone, quetiapine, risperidone, 
and ziprasidone. AAP users were classified as incident or new users (AAP users, 
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hereafter)  and included in the analysis if they met all of the following eligibility criteria: 
(1) initial dispensing date of an AAP (defined as the index date) was preceded by a 
minimum of six months of continuous enrollment (i.e., pre-index period) and was 
followed by a minimum of six months (or a year) of continuous enrollment in the health 
plan (i.e., post-index period); (2) did not have medical claims for conditions that are 
commonly treated with AAPs.ix; (3) had a 30 day or less gap between stimulant use and 
the index date; (4) had greater than 30 days accumulated stimulant supply during the 
pre-index period. As a comparison group, subjects were considered non-AAP users if 
they had at least one prescription for any of the non-stimulant ADHD drugs, which 
include atomoxetine, clonidine or guanfacine. Using the initial dispending date of these 
drugs as the index date for non-AAP users, the same sample selection criteria described 
above for the AAP users were applied to the non-AAP users. Additionally, subjects with 
both AAPs and non-AAP drugs during the observation period were excluded from 
analyses. A flow diagram describing the identification process for the groups included 
in the analyses is depicted in Figure 5. 1. 
The follow-up time for each subject started on the index date and was extended 
for six months (or a year) after the index date. This approach was intended in order to 
emulate an intention-to-treat analysis similar to randomized controlled trials.  
 
ix Those conditions were reported by Sikirica et al. and include schizophrenia (ICD-9-CM, 295), 
bipolar disorder (ICD-9-CM, 296.0; 296.1; 296.4-296.8), psychotic disorder with 
delusions/hallucinations (ICD-9-CM, 293.81; 293.82), paranoia (ICD-9-CM, 297.1; 297.3), psychosis 
(ICD-9-CM, 298.8; 298.9), tics/Tourett’s syndrome (ICD-9-CM, 307.2; 307.23), or dementia (ICD-9-
CM; 290, 294.1) 
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Outcome 
The outcome of interest in my study was health care service utilization and costs 
during six months (or one year) after the index date. Health care service utilization was 
assessed using the number of outpatient visits, inpatient visits, and emergency room 
visits. Total health care costs were calculated by adding total prescription costs to total 
medical costs. Total prescription costs were further categorized into index drug costs 
and non-index drug costs. Total medical costs were further categorized into mental 
health service related costs and non-mental health service related costs. For each 
category, costs associated with outpatient visits, inpatient visits, and emergency room 
visits were estimated. A mental health service refers to a medical visit with a primary 
diagnosis of a mental health disorder (ICD-9-CM 290.XX-319.XX). I used costs that 
occurred to third-party payers, which excludes deductibles, coinsurance, copayments 
and other out-of-pocket costs paid by patients. All costs were converted to 2012 US 
dollars based on the medical component of consumer price index.x  
 
Covariates 
To control for potential selection bias and confounding, I used the inverse 
probability of treatment weighting (IPTW) method in which each subject is weighted 
based on their inverse propensity to receive an AAP. The propensity for each subject 
was estimated through logistic regression as the probability of starting AAP treatment 
x Source: U.S. Department of Labor, Bureau of Labor Statistics. Consumer Price Index. Available 
at: http://www.bls.gov.cpi/. Accessed April 7, 2014) 
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during my study period, based on their baseline characteristics. Specifically, the 
following covariates were included: age, sex, race, geographic region, household income, 
primary health care payer source, the duration of stimulant use, the number of different 
stimulants used, the presence of hyperactivity in attention deficit disorder, the health 
care utilization intensity and physical/mental comorbidity during the pre-index period. 
Health care utilization was measured by four variables: the number of hospitalizations, 
the number of emergency room (ER) visits, the number of outpatient services, and the 
number of filled prescriptions with different generic names (excluding sitmulants). For 
comorbidity, we looked for conditions that are not only associated with AAP use, but 
also likely to affect health care costs/utilization. Those conditions include physical 
conditions such as obesity, diabetes, cardiovascular disease , and epilepsy, and mental 
conditions such as neurotic disorder, mood disorder, disturbance, developmental 
disorder, and adjustment disorder.  
 
Analysis 
 Baseline characteristics of AAP users and non-AAP users were compared and 
tested. All characteristics were included in the analysis as categorical variables and 
therefore, chi-square tests were used for all characteristics to assess statistical 
significances between the two cohorts. The additional health care costs accrued to AAP 
users compared to non-AAP users were estimated using the inverse probability of 
treatment weighting. The associated robust standard errors were derived from Taylor-
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linearized variances. Event rate ratios and 95% confidence intervals for health care 
service utilization were estimated using the Poisson regression model.  
 
C. Results 
 
Baseline characteristics  
 A total of 3,437 (2,189 for 12 month post-index observation cohort) patients met 
my inclusion criteria. Among those, 1,039 (639) individuals were new AAP users. 
Baseline characteristics of cohorts for the six month post-index observation period are 
summarized in Table 5. 1. At baseline, differences in patient demographics and 
socioeconomic characteristics between the two cohorts were not statistically different, 
except that AAP users were more likely to be older than non-AAP users (more 
adolescents and young adults). Instead, they were very different in terms of medical 
profiles and health care service utilization during the pre-index period. On average, 
AAP users used stimulants for a longer duration. Also, they were more likely to have 
hyperactivity in addition to the attention deficit disorder. While the presence of physical 
comorbidity was not statistically different between two cohorts, AAP users had a much 
higher rate of mental comorbidity. Also, the AAP users showed a higher level of health 
care utilization during the six month pre-index period, with respect to the number of 
outpatient service visits, hospitalizations, and filled prescriptions.  
 
Calculation of propensity scores  
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 The logistic regression model to evaluate AAP utilization is described in Table 5. 
2. The results indicate that older patients were more likely to receive an AAP. Female 
patients were less likely to receive an AAP compared to male patients. Annual 
household income was significantly associated with AAP use: the propensity to receive 
an AAP decreased as the level of household income increased. Compared to private 
insurance policy holders, Medicaid enrollees were less likely to use an AAP. While the 
longer duration of stimulant use increased the likelihood of using an AAP, the number 
of different stimulants used and the presence of hyperactivity did not show a significant 
impact on the AAP use. The higher level of health care utilization measured in the 
number of outpatient service visits and prescription medications significantly increased 
the propensity to receive an AAP. Also, having comorbid mental disorders including 
neurotic disorder, mood disorder and disturbance significantly increased the likelihood 
of AAP use. The c-statistic was 0.716, indicating a good predictive accuracy of the 
logistic regression model.  
 
Health Care Service Utilization 
 During the six month post-index observation period, over 96 percent of subjects 
utilized outpatient health care services one or more times. The average number of 
outpatient visits was ten per AAP user and seven per non-AAP user. From the Poisson 
regression analysis using IPTW, AAP users had a statistically significant increase in the 
likelihood of utilizing outpatient services than non-AAP users (event rate ratio, ERR 1.14; 
95% CI 1.04-1.26) (Table 5. 3). For inpatient service utilization, approximately five 
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percent of AAP users (N=53) and two percent of non-AAP users (N=40) were 
hospitalized at least once. The average number of outpatient visits was 0.08 per AAP 
user and 0.02 per non-AAP user. In the IPTW estimation, AAP users showed a 
statistically significant increase in the likelihood of being hospitalized than non-AAP 
users. (ERR 1.77; 95% CI 1.05-2.98). Nearly everyone in each cohort (≈99%) did not visit 
an emergency room (ER) during the six month observation period. The average number 
of ER visits was 0.01 per AAP user and 0.02 per non-AAP user. In the Poisson regression 
model with IPTW, ER visit rates between two cohorts were not significantly different.  
 During the 12 month post-index observation period, the relative rate of 
outpatient visits between AAP users and non-AAP users were similar to the result for 
the six month observation period (ERR 1.18; 95% CI 1.04-1.33). However, the rates of 
inpatient and ER visits were not significantly different between two cohorts. 
 
Additional Health Care Costs Accrued to AAP users 
 The average costs that are additionally accrued to AAP users compared to non-
AAP users were estimated using the inverse probability of treatment weighting and 
results are shown in Table 5. 4. During the six month observation period after index date, 
AAP users had higher health care costs especially associated with prescription 
medications and mental health related services. The prescription costs for AAP users 
were $900 higher than non-AAP users, mostly owing to the cost of their index drug. The 
mental health related service costs for AAP users were $509 higher than non-AAP users. 
Non-mental health related costs were not significantly different between two cohorts in 
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all categories of services. During the 12 month post-index observation period, the 
prescription costs remained higher for AAP users with additional $1,672 vs. non-AAP 
users. However, except mental health related outpatient visit costs, both mental health 
and non-mental health related medical costs were not significantly different between the 
two cohorts.  
 
D. Discussion 
 The purpose of the study was to compare health care resource utilization and 
costs between AAP users and non-AAP users in stimulant-treated ADHD patients. We 
found that AAP users were likely to visit a healthcare facility for outpatient and 
inpatient services more frequently than non-AAP users. Also, total health care costs 
were significantly higher for AAP users with additional costs of $1,393 during six 
months and $2,784 during a year after initiating the AAP treatment.  
 These findings are similar to the previous study conducted by Sikirica et al. 
Sikirica et al. used health administrative data collected from commercially insured 
members who were between ages sex and twelve. They reported that AAP users had a 
higher level of health care utilization and costs than non-AAP users during 12 months 
after index date. Interestingly, the additional total health care costs accrued to AAP 
users reported in their study are close to my result ($2,341, P<0.001 from Sikirica et al. vs. 
$2,784, P=0.007 from my study, both in 2012 dollars). However, it is different from my 
study in that their estimates were significantly higher for AAP users in all categories, 
while I observed the difference only in prescription costs and mental health related 
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outpatient service costs. There are a number of factors that could affect this difference, 
which include: (1) different sample size (larger for Sikirica et al.), (2) different age groups 
(more restricted for Sikirica et al.), and/or (3) different reimbursement policies 
implemented in different health insurance plans. 
 The additional total health care costs accrued to AAP users were mostly 
attributed to prescription medication costs, especially for the index drug. The additional 
expenses associated with the index drug for AAP users were $717 during the six month 
post-index period, and $1,249 during a year post-index period. This is probably due to 
the difference in drug price per unit. The average cost of risperidone, quetiapine and 
aripiprazole (the three most frequently used AAPs among pediatric patients) are 
estimated to be higher at $491 per month,100 as compared to $239 per month for 
atomoxetine  and $212 per month for clonidine/guanfacine.96 In addition, during 2007-
2009, none of the AAP agents were available as a generic drug while 
clonidine/guanfacine immediate release forms were available as generic drugs at the 
lower cost.   
 In the process of expanding the post-index observation period from six months 
to a year, we lost about a third of subjects (N=1,248). Many private health care 
enrollment decisions are made on a yearly basis, and requiring continuous enrollment 
during six month pre-index and one year post-index period would have excluded those 
who have changed their healthcare plan after a year of enrollment between January 1, 
2007 and December 31, 2009. Compared to those who were qualified for the one year 
post-index observation period (continuously enrolled for at least 12 months but less than 
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18 months, N=2,189), those who were qualified only for the six month post-index 
observation period (continuously enrolled for at least 12 months but less than 18 months, 
N=1,248) were more likely to be older (young adults, OR 1.85; 95% CI 1.42-2.42) and 
covered by Medicaid (OR 1.35; 95% CI 1.05-1.73). Also, they had a longer duration of 
baseline stimulant use (four to six months, OR 1.24; 95% CI 1.05-1.47), more stimulants 
(three or more different generic names, OR 1.39; 95% CI 1.04-1.87) and other prescription 
medications (four or more different generic names, OR 1.31 95% CI 1.04-1.66), and more 
comorbid mood disorders (OR 1.27; 95% CI 1.06-1.52). Considering that these 
characteristics are associated with not only the AAP use, but also the increase in health 
care service utilization, our estimates from the 12-month post-index observation period 
might have underestimated the true difference in health care costs and utilization 
between AAP users and non-AAP users. Another limitation of the study is a relatively 
short follow-up. Although the purpose was to assess the health care utilization and costs 
during six months or a year after initiating the index drug, the long-term effects of AAPs 
are potentially greater when considering the risk of chronic illness associated with AAPs, 
which may take a longer time to develop after drug initiation.  
 Despite such limitations, our study provides strong evidence to the debate 
related to pediatric AAP use. There are a number of concerns regarding AAP 
unapproved effectiveness and risks of developing chronic conditions including obesity, 
cardiovascular disease, and type II diabetes. Whereas much more evidence is focused on 
clinical benefits and risks of AAP use, empirical findings about the economic costs are 
under-provided. With ADHD as one of the leading conditions for a pediatric patient to 
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receive an AAP, I believe that the findings of the study will have important implications 
for the decision-making related to pediatric AAP use. 
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Figure 5. 1. Sample selection flowchart* 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*The number of subjects for 12 months post-index observation period is in parentheses.
ADHD patients (4 ≤ Age ≤ 24) who were continuously enrolled for 12 (or 18) months 
N=216,306 (N=162,243) 
Excluded: 
1. Having conditions that are commonly treated with AAPs; 
N=21,557 (N=15,491) 
2. Not having a stimulant prescription; N=36,060 (N=26,655) 
3. Not having an index drug prescription; N=131,912 (N=98,875) 
4. Not having 6 month pre-index and 6 (or 12) month post-index 
period; N=14,993 (N=13,496) 
5. Having >30 days between stimulant use and initial index drug 
use; N=7,139 (N=4,771) 
6. Having <30 days of stimulant supply during pre-index period;; 
N=75 (N=53) 
7. Having both AAP and non-AAP during post-index period; N=242 
(N=163) 
8. Patient demographic/socioeconomic characteristics not available; 
N=891 (N=550) 
 
 
AAP users before matching 
N=1,039 (N=639) 
Non-users before matching  
N=2,398 (N=1,550) 
Eligible study subjects 
N=3,437 (N=2,189) 
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Table 5. 1. Baseline characteristics – 6 month observation cohort 
 
 
Baseline Characteristics 
AAP users  
(N=1,039) 
Non-AAP users 
(N=2,398) 
 
 
p Value N % N % 
Age 
   Children (age 4-11) 503 48.41 1,463 61.01 <0.001 
   Adolescents (age 12-18) 447 43.02 793 33.07 <0.001 
   Young adults (age 18-24) 89 8.57 142 5.92 0.004 
Sex 
   Male 769 74.01 1,724 71.89 0.201 
   Female 270 25.99 674 28.11 0.201 
Race 
   White 858 82.58 2,015 84.03 0.292 
   Black 41 3.95 76 3.17 0.249 
   Other 140 13.47 307 12.80 0.591 
Region of residence 
   Northeast 103 9.91 190 7.92 0.055 
   Midwest 322 30.99 794 33.11 0.223 
   South 514 49.47 1,181 49.25 0.905 
   West 100 9.62 233 9.72 0.933 
Annual household income 
   ≤ $49,999 260 25.02 551 22.98 0.194 
   $50,000-74,999 281 27.05 643 26.81 0.888 
   $75,000-99,999 217 20.89 556 23.19 0.138 
   ≥ $100,000 281 27.05 648 27.02 0.989 
Payer source 
   Private 996 95.86 2,263 94.37 0.070 
   Medicaid 43 4.14 135 5.63 0.070 
Baseline stimulant use (duration) 
   ≤ 2 months 183 17.61 576 24.02 <0.001 
   2-4 months 378 36.38 876 36.53 0.933 
   4-6 months 478 46.01 946 39.45 <0.001 
Baseline stimulant use (number of different stimulant used) 
   1  720 69.30 1,705 71.10 0.287 
   2 266 25.60 577 24.06 0.335 
   3+ 53 5.10 116 4.84 0.743 
Attention deficit disorder with hyperactivity (ICD-9-CM, 314.01) 
   Yes 878 84.50 1,942 80.98 0.014 
   No 161 15.50 456 19.02 0.014 
Number of non-stimulant drugs prescribed (different generic names) 
   0-1 206 19.83 837 34.90 <0.001 
   2-3 415 39.94 986 41.12 0.520 
   4+ 418 40.23 575 23.98 <0.001 
Number of outpatient service visits 
   0-2 74 7.12 399 16.64 <0.001 
   3-5 298 28.68 886 36.95 <0.001 
   6-9 279 26.85 578 24.10 0.087 
   10+ 388 37.34 535 22.31 <0.001 
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Table 5. 1. Baseline characteristics –cont’d 
 
 
Baseline Characteristics 
AAP users  
(N=1,039) 
Non-AAP users 
(N=2,398) 
 
 
p Value N % N % 
Number of inpatient service visits 
   0 974 93.74 2,350 98.00 <0.001 
   1 51 4.91 43 1.79 <0.001 
  2+ 5 0.21 14 1.35 <0.001 
Number of emergency room visits 
   0 12 1.15 40 1.67 0.258 
   1+ 1,027 98.85 2,358 98.33 0.258 
Baseline physical comorbidity* 
   Obesity 17 1.64 32 1.33 0.493 
   Diabetes 6 0.58 7 0.29 0.210 
   Cardiovascular disease 4 0.38 9 0.38 0.966 
   Epilepsy 11 1.06 19 0.79 0.441 
Baseline mental comorbidity* 
   Neurotic disorder 245 23.58 315 13.14 <0.001 
   Mood disorder 286 27.53 217 9.05 <0.001 
   Disturbance 249 23.97 324 13.51 <0.001 
   Developmental disorder 58 5.58 147 6.13 0.533 
   Adjustment disorder 135 12.99 244 10.18 0.015 
*These variables are not mutually exclusive. 
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Table 5. 2. Propensity score model of receiving an atypical antipsychotic medication 
Confounder Odds ratio 95% Confidence interval 
Age 
   Children (age 4-11) Reference  
   Adolescents (age 12-18) 1.47* 1.24-1.75 
  Young adults (age 19-24) 1.59* 1.16-2.19 
Sex 
   Male Reference  
   Female 0.76* 0.63-0.91 
Race 
   White Reference  
   Black 1.65* 1.10-2.51 
   Others 1.09 0.86-1.38 
Region of residence 
   Northeast Reference  
   Midwest 0.70* 0.52-0.94 
   West 0.82 0.57-1.18 
   South 0.76 0.57-1.01 
Annual household income 
   ≤ $49,999 Reference  
   $50,000-74,999 0.83 0.66-1.04 
   $75,000-99,999 0.66* 0.52-0.84 
   ≥ $100,000 0.71* 0.56-0.89 
Payer source 
   Private Reference  
   Medicaid 0.59* 0.39-0.89 
Baseline stimulant use (duration) 
   ≤ 2 months Reference  
   2-4 months 1.39* 1.14-1.71 
   4-6 months 1.98* 1.59-2.48 
Baseline stimulant use (number of different stimulant used) 
   1  Reference  
   2 1.01 0.84-1.22 
   3+ 0.95 0.66-1.37 
Attention deficit disorder with hyperactivity (ICD-9-CM, 314.01) 
   No Reference  
   Yes 1.16 0.94-1.44 
Number of non-stimulant drugs prescribed (different generic names) 
   0-1 Reference  
   2-3 1.39* 1.14-1.71 
   4+ 1.98* 1.59-2.48 
Number of outpatient service visits 
   0-2 Reference  
   3-5 1.49* 1.12-2.00 
   6-9 1.80* 1.32-2.45 
   10+ 2.27* 1.64-3.13 
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Table 5. 2. Propensity score model of receiving an atypical antipsychotic medication-
cont’d 
Confounder Odds ratio 95% Confidence interval 
Number of inpatient service visits 
   0 Reference  
   1 1.17 0.74-1.87 
  2+ 2.55 0.74-8.80 
Number of emergency room visits 
   0 Reference  
   1+ 0.45 0.20-1.00 
Baseline physical comorbidity 
   Obesity 0.83 0.45-1.51 
   Diabetes 1.19 0.30-4.77 
   Cardiovascular disease 0.75 0.21-2.66 
   Epilepsy 1.03 0.44-2.42 
Baseline mental comorbidity 
   Neurotic disorder  1.39* 1.12-1.72 
   Mood disorder 2.54* 2.03-3.17 
   Disturbance 1.79* 1.45-2.21 
   Developmental disorder 0.81 0.57-1.14 
   Adjustment disorder 0.94 0.73-1.21 
*Significant at 5% significance level. 
 
 
 
 
 
 
 
 
 
 
 
 
 
105 
 
Table 5. 3. Inverse probability of treatment weighted estimation of health care utilization 
of AAP users compared to non-AAP users  
 
 
 
Health care utilization 
During 6 month observation 
period after index date (N=3,437) 
During 12 month observation 
period after index date (N=1,908) 
Event rate ratio 
 (95% confidence 
interval) 
p 
Value 
Event rate ratio  
(95% confidence 
interval) 
p 
Value 
Outpatient service visits 1.14 (1.04-1.26) 0.008 1.18 (1.04-1.33) 0.009 
Inpatient service visits 1.77 (1.05-2.98) 0.033 1.48 (0.92-2.40) 0.108 
Emergency room visits 0.62 (0.23-1.65) 0.342 0.99 (0.33-3.02) 0.988 
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Table 5. 4. Inverse probability of treatment weighted estimation of incremental costs 
accrued to AAP users compared to non-AAP users  
 
 
Health care costs 
During 6 month observation period 
after index date (N=2,895) 
During 12 month observation 
period after index date 
(N=1,908) 
Incremental cost 
(± robust standard 
error) p Value 
Incremental cost 
(± robust standard 
error) 
p 
Value 
Total prescription costs          $ 900 (± 63) <0.001          $ 1,672 (± 155) <0.001 
   Index drug costs          $ 717 (± 35) <0.001          $ 1,249 (± 87) <0.001 
   Non-index drug costs          $ 184 (± 48) <0.001             $ 423 (± 115) <0.001 
Total medical costs          $ 493 (± 350) 0.159          $ 1,113 (± 1,008) 0.270 
   Mental health related costs          $ 509 (± 170) 0.003             $ 573 (± 232) 0.014 
      - Outpatient visits          $ 196 (± 78) 0.012             $ 293 (± 157) 0.062 
      - Inpatient visits          $ 314 (± 139) 0.024             $ 281 (± 147) 0.057 
      - Emergency room visits             -$ 0.2 (± 0.3) 0.485                -$ 1 (± 1) 0.092 
   Non-mental health related costs           -$ 16 (± 282) 0.954             $ 539 (± 973) 0.580 
      - Outpatient visits          $ 124 (± 226) 0.583             $ 797 (± 868) 0.359 
      - Inpatient visits         -$ 135 (± 122) 0.265            -$ 258 (± 275) 0.348 
      - Emergency room visits             -$ 5 (± 4) 0.222                 $ 0.3 (± 11) 0.979 
Total health care costs*       $ 1,393 (± 362) <0.001          $ 2,784 (± 1,031) 0.007 
*Total prescription costs + total medical costs 
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Chapter 6: Conclusion and Policy Recommendations 
 
 The extensive use of AAPs by pediatrics is an important policy problem that 
imposes serious concerns on public health and economy in the US. As discussed in 
chapter 2, a large proportion of total pediatric AAP use is off-label in which the safety 
and effectiveness are not yet established. Moreover, among the off-label conditions for 
which AAPs were used, ADHD was the most common primary mental diagnosis.  
Motivated by this phenomenon, this dissertation further addressed underlying problems 
about AAP utilization, and its implication to ADHD children and adolescents.  
From public health perspective, the risk of type II diabetes in pediatric AAP 
users was estimated in chapter 3. A retrospective cohort study was conducted using 
nationally representative data, and the twice higher risk of developing type II diabetes 
was estimated for AAP users compared to non-users in pediatrics. Considering that 
T2DM is a chronic condition that may persist the rest of a person’s life, its risk that is 
imposed on children and adolescents could outweigh the benefit of AAP therapy in 
some patients.    
From economic efficiency perspective, chapter 4 estimated the cost-effectiveness 
of AAPs compared to other ADHD medications in pediatric ADHD patients who have 
failed a stimulant therapy. Among non-stimulant ADHD medication treatment 
strategies, AAPs resulted in the lower expected health outcome than other ADHD 
medications including atomoxetine, clonidine, or guanfacine. Also, AAPs were not a 
favored choice with respect to cost-effectiveness, and should not be recommended over 
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other strategies. While analyses in chapter 4 were based on estimates derived from 
literature review, the chapter 5 reports an original study that compares resource 
utilization and costs between atypical antipsychotic (AAP) users and non-AAP users in 
ADHD. I found that AAP users were likely to visit a healthcare facility for outpatient 
and inpatient services more frequently than non-AAP users. Also, total health care costs 
were significantly higher for AAP users with additional costs of $1,393 (2012 dollars) 
during six months and $2,784 (2012 dollars) during a year after initiating the AAP 
treatment.  
With the defined problem and evidences reported in this dissertation, I propose 
solutions and policy recommendations that can be implemented at the national/state 
government level, the health care provider level and the patient/caregiver level.  
First, at the national/state government level, it is important for healthcare service 
agencies to recognize that the pediatric AAP use is a potentially inappropriate 
utilization. Especially, as primary public organizations involved in regulating mental 
health service provision, Substance Abuse Mental Health Services Administration 
(SAMHSA), Centers for Medicare and Medicaid Services (CMS), and National 
Association of State Mental Health Program Directors (NASMHPD) should work 
together so that their funding and billing systems reflect the promotion of standardized 
mental health care. Also, current health care surveillance activities could be amended in 
a way that the pediatric AAP practice and its impacts are better captured and assessed 
by health services researchers. For example, Healthcare Effectiveness Data and 
Information Set (HEDIS) is a widely used set of healthcare quality measures in the US. 
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While it incorporates a number of measures that assess mentally ill patients’ access to 
healthcare services and medication managements, it does not include a measure for 
assessing the potential overuse or misuse of antipsychotics. It is recommended that 
standard definitions for identifying inappropriate antipsychotic use are developed and 
included in the HEDIS and other healthcare quality surveillance tools. 
Second, at the healthcare provider level, provider agencies and clinicians should 
ensure the provision of quality and evidence based care. One of the reasons why AAPs 
were largely used by pediatrics is because they were marketed as a safer choice 
compared to typical antipsychotics. However, when making decisions about the AAP 
therapy, it should be thoroughly considered that the risk of using an AAP may outweigh 
benefits in many children and adolescents.  
Third, at the patient/caregiver level, they are encouraged to pursue patient 
centered care that is long-term wellness focused. Patient-centered care is defined as 
“care that is respectful and responsive to individual patient preferences needs, and 
values and ensuring that patient values guide all clinical decisions”. It would be better 
implemented if patients/caregivers share information so that the mental health 
community becomes more aware of the clinical/economic impacts of pediatric AAP use. 
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